Immunotherapeutic Strategies to Reverse Tumor Associated Immunosuppression in Breast Cancer by Ravindranathan, Sruthi
University of Arkansas, Fayetteville
ScholarWorks@UARK
Theses and Dissertations
12-2016
Immunotherapeutic Strategies to Reverse Tumor
Associated Immunosuppression in Breast Cancer
Sruthi Ravindranathan
University of Arkansas, Fayetteville
Follow this and additional works at: http://scholarworks.uark.edu/etd
Part of the Immunoprophylaxis and Therapy Commons
This Dissertation is brought to you for free and open access by ScholarWorks@UARK. It has been accepted for inclusion in Theses and Dissertations by
an authorized administrator of ScholarWorks@UARK. For more information, please contact scholar@uark.edu, ccmiddle@uark.edu.
Recommended Citation
Ravindranathan, Sruthi, "Immunotherapeutic Strategies to Reverse Tumor Associated Immunosuppression in Breast Cancer" (2016).
Theses and Dissertations. 1814.
http://scholarworks.uark.edu/etd/1814
  
Immunotherapeutic Strategies to Reverse Tumor Associated Immunosuppression in Breast 
Cancer 
 
 
A dissertation submitted in partial fulfillment 
of the requirements for the degree of 
Doctor of Philosophy in Biomedical Engineering 
by 
Sruthi Ravindranathan 
Anna University 
Bachelor of Engineering in Biomedical Engineering, 2010 
University of Arkansas 
Master of Science in Biomedical Engineering, 2013 
 
December 2016 
University of Arkansas 
 
This dissertation is approved for recommendation to the Graduate Council. 
 
 
_______________________________                     
Dr. David A. Zaharoff                                               
Dissertation Director                                                  
_______________________________                      _______________________________                       
Dr. Gisela F. Erf                                                          Dr. Timothy J. Muldoon 
Committee Member                                                    Committee Member 
_______________________________ 
Dr. Narasimhan Rajaram 
Committee Member 
 
  
Abstract 
Heterogenous cancers such as breast carcinoma, would highly benefit from personalized vaccine 
approaches such as autologous tumor cell vaccines (ATCVs). By using cancer cells that are 
isolated from self, this approach has the potential to generate a polyclonal immune response 
against tumor antigens, that are specific to the individual. However, so far, ATCVs against breast 
cancers have not had any clinical success due to the poor immunogenicity of the malignant cells.  
In this study, for the first time, we determined tumor derived G-CSF to play a major role in 
affecting immune response against breast cancer ATCVs. By using CRISPR/Cas9 genome 
editing technology, we found that tumor derived G-CSF results in the accumulation of 
exceptionally high levels of myeloid derived suppressor cells (MDSCs) in the spleen and lymph 
nodes of immunized mice. For the first time, we demonstrated that by eliminating G-CSF in 
ATCVs, the overall efficacy of the vaccine can be significantly improved. Further, for the first 
time, by using breast cancer cells that naturally produce varying levels of G-CSF, we 
reestablished the effect of G-CSF on splenic MDSC accumulation.  
Additionally, we addressed the MDSC associated immunosuppression, by investigating 
strategies to facilitate the maturation of immature immune cells. We considered different 
commercially available toll like receptor (TLR) agonists namely Pam3CSK4 (Pam), Poly (I:C), 
lipopolysaccharide, FLA-ST, FSL-1 and R848, and compared their effect on MDSC maturation 
in-vitro. Of all the agonists, we found that only Pam resulted in the complete maturation of 
MDSCs since it resulted in the upregulation of all four MDSC maturation markers, CD80, CD86, 
MHCII and F4/80. Additionally, Pam also significantly reduced the number of MDSCs in the 
treated whole splenocyte cultures.   
  
Future studies that are discussed here will expand our knowledge on the effect of tumor derived 
G-CSF in clinical cancer burden and metastasis of breast cancer. Further, in-vivo studies with the 
TLR agonists, would help design an effective adjuvant therapy against aggressive and metastatic 
breast cancers, with improved survival and reduced rate of recurrence.  
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I. INTRODUCTION 
A. Introduction to breast cancer 
Worldwide, breast cancer is the most commonly diagnosed cancer in women, accounting for 
25% of all cases. In U.S alone about 230,000 new breast cancer cases are diagnosed every year. 
Overall, there are 2.8 million women in U.S who are currently being treated or have completed 
treatment for breast cancer. It is also the second leading cause of cancer death in U.S women 
with about 40,500 deaths in 2015 (1). 
Breast cancer is the presence of malignant cells in the breast region. These cells either originate 
in the lobules, the milk producing glands or ducts, the tubes that carry milk to the nipple. Based 
on its ability to invade the surrounding normal tissue, the cancer is categorized as benign or 
malignant. Benign breast tumors are not life threatening since they remain enclosed within the 
region of origin. On the contrary, malignant tumors are cancerous and can be life threatening if 
left unchecked. Unfortunately, 1 in 8 women in U.S will develop invasive breast cancer in her 
lifetime. These malignant cells can eventually invade distant organs in the body such as the bone, 
liver, lungs or brain, in which case it is termed as metastatic breast cancer. It is estimated that 20-
30% of all breast cancer cases will become metastatic (2). 
B. Stages and types of breast cancer 
Breast cancer is usually categorized into five stages from 0 to IV. Stage 0 denotes non-invasive 
breast cancer, where there is no evidence of the malignant cells breaching the surrounding 
normal tissue. On the contrary, stage IV denotes the advanced stages of the disease where the 
cancer has metastasized to distant lymph nodes and/or other organs of the body such as the 
lungs, brain, bone, skin or liver (3). Early diagnosis is paramount in breast cancer treatment since 
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once the cancer spreads to neighboring lymph nodes (stages III and IV), it becomes extremely 
challenging to eliminate the disease (4).  
Further, invasive breast cancer is categorized into three different phenotypes, namely hormone 
receptor positive (HR+), human epidermal growth factor receptor positive (HER-2+) and triple 
negative breast cancer (TNBC) based on the surface marker expression. For instance, patients 
with breast cancer cells expressing estrogen or progesterone receptors are classified as hormone 
receptor positive. This is the most commonly diagnosed type of breast cancer with approximately 
2 out of 3 patients testing positive for the hormone receptors (5). On the other hand, patients 
whose cancer cells overexpress HER-2 are classified as HER-2 positive.  About 25-30% of 
breast cancer patients are HER2+ with significantly reduced disease free survival and poor 
prognosis (6). The third type, triple negative breast cancer (TNBC) is the most aggressive type 
accounting for 10-20% of the patients. Malignant cells of patients with TNBC do not express 
hormone or HER-2 receptors, rendering it extremely difficult to target these cells during therapy. 
Additionally, TNBC has extremely poor prognosis and tends to recur early when compared to 
the other subtypes of breast cancer (7). 
C. Primary treatment  
Primary treatment for breast cancer involves complete removal of the tumor via surgery. Based 
on the size of the tumor, patients undergo lumpectomy, where only part of the breast with cancer 
is removed or mastectomy where the entire breast tissue is removed (1). However, patients with 
invasive breast cancer usually always undergo axillary lymph node dissection (ALND), where 
some or all lymph nodes near the breast are removed. Sometimes ALND is also recommended in 
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patients with early stages of the disease as a preventive measure to minimize the chances of 
metastasis. 
Unfortunately, patients undergoing ALND often suffer from lymphedema, where there is 
excessive swelling of the arm post-surgery. This condition is considered as an incurable side 
effect that leads to extreme discomfort and restricted arm movement (8). Thus, a comparatively 
new form of surgery, that overcomes this side effect is sentinel lymph node biopsy (SLNB). This 
technique involves the injection of radioactive drugs or dyes to the cancer, which help physicians 
to detect sentinel lymph nodes, the first lymph nodes that the tumor drains into. By first testing 
these lymph nodes for the presence of cancer cells, the need for any further surgery is assessed. 
Thus, SLNB is a minimally invasive procedure that prevents any unnecessary removal of lymph 
nodes from breast cancer patients. Studies comparing SLNB and ALND over the past few years 
have established the consistent low false negative rates associated with SLNB (9, 10). 
D. Adjuvant therapy 
Breast cancer cells that escape the breast and regional lymph nodes, if left unchecked have the 
potential to metastasize and result in recurrence after primary surgery. Thus, usually patients 
with invasive breast cancer after undergoing primary treatment, are recommended to undergo 
additional therapy to eliminate these residual cancer cells. Such therapies are collectively known 
as adjuvant therapy. Different types of adjuvant therapy are recommended based on the size of 
the tumor and the extent of its spread. The most commonly used adjuvant therapies for breast 
cancer are chemotherapy, radiation therapy and hormonal therapy (11). 
Chemotherapy is a systemic therapy where medicines that destroy rapidly multiplying cancer 
cells are administered to the patient post-surgery. Though chemotherapy is associated with 
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reduction in recurrence in 35% of women under the age of 50 years, the short and long term side 
effects of the therapy cannot be overlooked. Some of the acute side effects of chemotherapy 
include neutropenia, nausea, vomiting, loss of appetite and alopecia. Premenopausal women also 
suffer from long term side effects such as damage of ovaries leading to premature menopause 
and/or infertility (1, 11, 12).  
Radiation therapy uses high energy particles such as x-rays or gamma rays to kill the residual 
malignant cells. Unlike chemotherapy, radiation therapy is comparatively targeted at the 
malignant cells. Thus, the side effects of the therapy are limited to the treated region. It is offered 
to patients with stage I or II breast cancer, after lumpectomy. It is also recommended after 
mastectomy in patients whose cancer has spread to the lymph nodes. Despite being a 
comparatively targeted therapy, radiation therapy is not devoid of side effects. The most 
prevailing side effect is brachial plexopathy due to damage of nerves near the neck region. The 
intense radiation also results in a feeling of heaviness in the breast region and change in the color 
of skin over the breast (13). 
Hormonal therapy on the other hand, is only given to patients whose cancers are hormone 
receptor positive. Here, drugs that either block the body’s ability to release the hormones or 
those that interfere with the function of the hormone are used to stop tumor growth. Since the 
hormones are blocked during therapy, a major drawback of this form of treatment is interruption 
of the menstrual cycle. Additionally, patients also suffer from hot flashes, vaginal dryness, 
swelling of the breasts and decreased bone mineral density (14, 15). Also, studies have shown 
that, Tamoxifen, the most commonly used drug in hormonal therapy, increases the risk of 
endometrial cancer and venous thromboembolism (16). 
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From the discussion, it is evident that current adjuvant therapies are associated with numerous 
side effects that overshadow the treatment benefits. Additionally, since one cannot predict the 
fate of tumor after surgery, patients whose tumor would not have resulted in clinically apparent 
disease post-surgery, still undergo therapy and suffer from the side effects. Thus, the need to 
undergo adjuvant therapies is a lingering debate in patients with early stages of the disease (17). 
Also, it is important to note that 90% of breast cancer deaths are still due to recurrence and 
metastasis, corroborating the ineffectiveness of prevailing adjuvant therapies. Thus, it is 
indisputable that there is a compelling need to develop more effective, tumor specific and less 
toxic adjuvant therapies to improve survival in breast cancer patients. 
E. Immunotherapy 
Cancer immunotherapy is the technique of stimulating the patient’s immune system to recognize 
and eradicate cancerous cells. Since this technique ‘trains’ the immune system to identify cancer 
cells, it is expected to have long lasting remission unlike most conventional therapies. 
Additionally, since immunotherapy specifically targets malignant cells, patients are less likely to 
suffer from adverse side effects. Thus, cancer immunotherapy is being considered a 
breakthrough in cancer treatment with promising potential in improving clinical outcomes. It is 
an umbrella term that includes different strategies such as antibody based therapy, checkpoint 
therapy and cell based vaccines. In breast cancer treatment, trastuzumab was the first antibody 
based immunotherapy approved in 1998. It is a monoclonal antibody that interferes with 
HER2/neu receptor, overexpressed by cancer cells in HER2+ patients (18). Since then, numerous 
immunotherapies have emerged and more are in preclinical studies or clinical trials.  
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For instance, pertuzumab and lapatinib are other HER2 directed antibody based drugs recently 
approved by FDA for treatment of advanced stages of HER2+ breast cancer. In these therapies, 
the efficacy largely depends on the tumor antigen chosen for treatment. If the chosen antigen is 
expressed homogenously and frequently by the malignant cells, the therapy is likely to be 
effective. Additionally, targeting an antigen that is exclusively upregulated in tumor cells, 
minimizes the chances of adverse side effects (19). However, it is important to note that the high 
specificity does not make these therapies devoid of adverse side effects. For instance, 
trastuzumab therapy increases the likelihood of heart damage leading to congestive heart failure. 
Moreover, the cardiac toxicity exacerbates when the drug is used in conjunction with other 
treatment regimens such as anthracycline (20). 
Checkpoint therapy involves the use of drugs that specifically target checkpoint receptors or 
ligands. These receptors/ligands are literally ‘checkpoints’ of the immune system that assist in 
preventing autoimmune responses. Although this is an extremely important mechanism in 
preventing detrimental effects of autoimmunity, it greatly affects immunotherapeutic strategies. 
Thus, blocking them could provoke an anti-tumor response or improve its likelihood when used 
in combination with other therapies (21). Several checkpoint inhibitors such as Iplimumab, 
pembrolizumab and nivolumab, that were initially approved for melanoma treatment are under 
investigation for breast cancer (22).  
Additionally, in 2010, FDA approved sipuleucel-T, an autologous cellular vaccine for patients 
with hormone-refractory metastatic prostate cancer (23). Since then different cellular vaccines 
are under clinical and pre-clinical studies for treatment of different cancers. Cellular vaccines 
usually involve the adoptive transfer of T cells that are engineered to enhance anti-tumor 
response. In an ongoing phase I trial, T cells engineered to target carcinoembryonic antigen 
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(CEA), that are often expressed on breast cancer cells are utilized (24). Similarly, there are also 
ongoing studies on using dendritic cell vaccines for breast cancer. These vaccines work by 
initiating the expansion of CD4+ and CD8+ T cells specific for the tumor (25).  
Though peptide based vaccines and adoptive therapy are feasible strategies, they are limited by 
some disadvantages. For instance, peptide based vaccines only recognize a few epitopes on the 
cancer cells and therefore can only be used for patients with cancers expressing the specific 
antigen (23). Adoptive therapy on the other hand, is limited by the need for repetitive 
administration of the drug to sustain the anti-tumor response (26). An immunotherapeutic 
technique that overcomes these disadvantages is the whole tumor cell vaccine. These vaccines 
are made from either autologous or allogenic tumor cells. The allogenic tumor cell vaccine uses 
tumor cells isolated from multiple established tumor cell lines. Since various cell lines have 
overlapping antigen expression profile, the allogenic tumor cell vaccines have the potential to 
activate a tumor specific immune response via cross priming (23). On the other hand, autologous 
tumor cell vaccine (ATCV) is made from cancer cells obtained from the patient (27). ATCVs are 
a rich source of all tumor associated antigens (TAAs) unique to the patient’s tumor. These 
vaccines thus have the advantage of activating a polyclonal immune response specific to the 
individual’s cancer (28). Since ATCVs would highly benefit patients with heterogenous cancers 
such as the breast, in the past decade several pre-clinical studies have been focusing on 
developing effective ATCVs for breast cancer (29).   
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II. IMMUNOSUPPRESSION IN ADVANCED STAGES OF BREAST CANCER 
A. Introduction 
Over the past few years, our knowledge of breast cancer has greatly improved and so have the 
treatment methods. Early detection along with new therapeutic strategies have decreased the 
mortality rate by about 37% over 25 years (30). However, unfortunately, most of the newly 
developed therapies are targeted only at a specific population such as the human epidermal 
growth factor 2 positive (HER2+) or estrogen receptor positive (ER+) or patients with non-
invasive breast cancer. However, patients with the more aggressive forms such as triple negative 
breast cancer are not provided with enough treatment options. Unfortunately, these patients make 
for about 15-20% of breast cancers diagnosed every year. Additionally, 20-30% of patients with 
early stage breast cancer, go on to develop metastatic breast cancer and 6-10% of all invasive 
breast cancers are already metastatic at initial diagnosis (31). Unfortunately, the treatment 
options for these patients are extremely slim and is generally palliative.   
Per literature, a major hindrance in the treatment of these aggressive forms of breast cancers is 
the tumor associated immunosuppression (32). Cancer immunosuppression involves the 
generation of an immunosuppressive environment mediated by various tumor derived factors 
such as transforming growth factor-β (TGF-β) and vascular endothelial growth factor (VEGF) 
(33). These factors in turn cause the expansion of immunosuppressive immune cells such as 
regulatory T cells (Tregs) and immature myeloid cells that assist the tumors to evade the immune 
system. Not so surprisingly, such an immunosuppressive environment could also affect the 
success of several therapeutic strategies against these cancers. Thus, currently several studies are 
investigating the different immunosuppressive pathways associated with breast cancer. There are 
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also a few studies where new pathways of immunosuppression have been discovered and their 
correlation with tumor progression is being investigated. 
Thus, this review highlights the major players of immunosuppression found in advanced stages 
of breast cancer and their correlation with poor prognosis or metastatic burden.  Understanding 
these pathways, could help researchers develop better immunotherapeutic drugs or vaccines and 
improve overall survival of breast cancer patients.   
B. Identifying major players of immunosuppression 
In recent years, breast tumor microenvironment is widely studied to determine the different 
tumor infiltrating lymphocytes and growth factors/cytokines that affect the overall immune 
response. Interestingly, a few subsets of immunosuppressive cells have been recently identified 
in breast tumors, and were found to contribute to cancer progression and metastasis. 
Regulatory T cells 
FoxP3+ regulatory T cells (Tregs) are an immunosuppressive subset of T cells that have been 
greatly investigated in different cancer models (34-37). In breast cancer, several studies have 
reported an increased enrichment of tumor infiltrating lymphocytes (TILs) with Tregs to 
correlate with poor prognosis and high risk of cancer recurrence (38-40). For instance, in a study 
that included patients with invasive and ductal carcinoma in-situ (DCIS), Tregs were found at 
significantly higher frequencies in invasive tumor samples than in DCIS. Further, in the patients 
with invasive tumor, the higher levels of Tregs inversely correlated with positive node status, 
relapse free survival (RFS) and overall survival (OS). Additionally, a population of ER+ patients 
with high frequency of Tregs were found to be at a higher risk of shorter RFS and OS, when 
compared to ER positive patients with lower levels of Tregs (40). Similarly, in another study, 
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upon analysis of tumors removed from 100-treatment naïve breast cancer patients, it was found 
that the frequency of Tregs in triple negative breast cancer was the highest (38). Thus, these 
studies proposed that high risk breast cancer patients can be identified via quantifying Tregs in 
their tumor biopsies. 
Recently, FoxP3, the transcription factor that plays a crucial role in the immunosuppressive 
property of Tregs, was also found to be expressed by breast cancer cells. This was surprising, 
since it was initially thought to be expressed only by cells of the lymphocyte lineage (41, 42). 
Additionally, the heterogeneous localization (nucleus/cytoplasm) of FoxP3 in cancer cells was 
found to have prognostic value, since the presence of cytoplasmic FOXP3 correlated with poor 
OS (43). However, the findings from this study completely contradicted another study where 
cytoplasmic FOXP3 expression improved OS and RFS in patients with HER2+ breast cancer 
(42). Nonetheless, it is important to note that the former study used treatment naïve breast cancer 
patients, whereas the latter collected samples from patients who had undergone neoadjuvant 
chemotherapy. Thus, the possibility of the discrepancy to be because of chemotherapy, cannot be 
ruled out until further investigation.  
Further, in another study, a new subset of Tregs were found at significantly higher levels in TILs 
and peripheral blood of patients with advanced stages of breast cancer. These cells were found to 
express CCR6 and high levels of CD45RO and were termed as CCR6+ Tregs. Unlike the CCR6- 
Tregs, the frequency of these cells in the TILs of patients with advanced stages (stage III and IV) 
of the disease was significantly higher than in patients with early stages (stage I and II). There 
was also a correlation between the presence of CCR6+ Tregs and the decreased levels of IFN-γ 
producing CD8+ T cells. Upon further analysis, this subset of Tregs was also found to inhibit 
CD4+ T cells at significantly higher levels than their CCR6- counterpart (44). 
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Regulatory B cells 
Like the Tregs, recently another population of regulatory immune cells were identified in mouse 
models of chronic inflammation. These were termed as regulatory B cells (Bregs), since they 
were a population of B cells that produced IL-10 and/or TGF-β and were involved in 
immunosuppression (45). However, as of now, a unique marker for Bregs has not yet been 
identified. Therefore, among the different studies, there are slight differences in the markers used 
to identify Bregs. Most of the studies in human breast cancers identifies these cells as IL-10 
(high) and TGF-β (high) producing B cells that are also CD19+, CD25high, CD86high and 
CDd1high. In an in-vitro study, when these cells were co-cultured with stimulated CD4+ T cells, 
they were found to significantly decrease the proliferation of CD4+ T cells. Additionally, the 
Bregs were also found to increase the immunosuppressive capacity of Tregs by upregulating the 
expression of FoxP3 and CTLA-4. However, this effect on Tregs was contact dependent (46).  
In the 4T1 murine breast cancer model, another unique subset of Bregs were recently reported. 
These cells belonged to CD19, CD25 and B220 expressing B2 lymphocytes that were found to 
be needed for metastasis of the cancer to lungs. These cells were labelled as tumor evoked Bregs 
(tBregs) and they were found to initiate the conversion of non-Tregs into Tregs in-vivo (47).  
Myeloid derived suppressor cells 
Another immunosuppressive immune cell subset found in the tumor microenvironment of most 
solid tumors are the myeloid derived suppressor cells (MDSCs) (48). These cells express CD11b, 
CD33 and low levels of HLADR, in humans, whereas they are double positive for CD11b and 
Gr1 in mice (49). These cells are known to involve in immunosuppression by releasing different 
immunosuppressive factors such as arginase and reactive oxygen species (48). 
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In breast cancer patients, the presence of MDSCs in peripheral blood and its association with 
cancer stage and metastasis, has been widely investigated. Peripheral blood samples collected 
from breast cancer patients were found to have significantly higher levels of MDSCs when 
compared to healthy volunteers (50). Additionally, the levels of MDSCs were found to closely 
correlate with tumor burden (49, 50). Thus, it was also proposed that these cells could possibly 
provide predictive information on human breast cancer stage. Consequently, it was found that, 
patients with stage IV breast cancer had the highest peripheral blood level of MDSCs, which 
were sometimes as high as 25%. Corroborating this finding, in another study, patients with 
metastatic breast cancer with abnormal levels of MDSCs in peripheral blood were found to have 
decreased OS (51).  
Further research on MDSCs revealed the presence of two subsets, namely granulocytic MDSCs 
(G-MDSCs) and monocytic MDSCs (M-MDSCs). In mice, MDSCs that are Ly6G+ Ly6Clow are 
termed as granulocytic, whereas Ly6G-Ly6Chigh are monocytic MDSCs. However, in humans 
MDSCs that are CD33+Lin- and CD14+ HLA-DRlow/- co-receptorlow/- are termed as granulocytic 
and monocytic MDSCs, respectively (52).  Though a few studies have compared the frequency 
and immunosuppressive capacity of these two subsets in breast cancer, the findings are 
contradicting. In some studies, M-MDSCs were found at elevated levels in the peripheral blood 
of breast cancer patients and it correlated with levels of dissemination of the disease (52). 
However, in a few other studies, granulocytic MDSCs were found at higher levels (50, 53). Thus, 
further investigation is required to characterize these subsets in human breast cancer and 
determine their effect on cancer progression. 
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Circulating tumor cells  
Circulating tumor cells (CTCs) is another recently identified prognostic marker of breast cancer. 
The presence of CTCs in peripheral blood is often termed as ‘carcinocythemia’ and is frequently 
found in patients with metastatic breast cancer (54). In a few case reports, the presence of CTCs 
in peripheral blood correlated with cancer progression and OS (55-57). Though, it is not clearly 
understood how CTCs affect the immune response, a few studies have pointed out some 
noticeable differences in the anti-tumor immunity of CTC positive patients. In a study where 
peripheral blood from metastatic breast cancer patients were analyzed, it was found that patients 
with ≥ 5 CTCs/7.5ml of blood had decreased NK cell function when compared to patients with 
<5 CTCs (58, 59). Similarly, in another study, significant differences were found in the TLR 
expression of dendritic cells between patients with and without CTCs. Patients with CTCs had 
decreased expression of TLR3 and increased expression of TLR2, TLR4 and TLR8, when 
compared to patients without CTCs (60). Interestingly, in another study involving patients with 
primary breast cancer, no differences in number of cytotoxic T cells (CD8+) and T-helper cells 
(CD4+)/µl were found between CTC positive and negative patients. However, a significant 
upregulation in the expression of CD95(FAS) was observed in the CD4+ T cells of CTC positive 
patients. Since the CD95/CD95L pathway is known to induce apoptosis, it is postulated that the 
cancer cells in CTC positive patients are inducing apoptosis of T helper cells, resulting in a 
dysfunctional immune response (61).  
C. Conclusion 
Tumor associated immunosuppression could be a major hindrance in developing 
immunotherapies against advanced stages of breast cancer. A review of the literature identifies 
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several immunosuppressive cell populations such as MDSCs, Tregs and Bregs in the tumor site 
or in the lymphoid organs of breast cancer patients. Additionally, recent research has identified 
unique subsets of immunosuppressive immune cells such as CCR6+ Tregs, that correlate with 
disease progression and/or response to therapy. However, it is important to note that not all 
subsets are fully characterized in human breast cancers. Additional investigations are required to 
reiterate their correlation with clinical cancer stage and determine their effect on 
immunotherapies. Also, understanding their pathways of development could help researchers 
identify molecules or drugs that could inhibit their generation and improve survival.  
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III. G-CSF SECRETED BY AUTOLOGOUS TUMOR CELL VACCINE 
ABROGATES TUMOR SPECIFIC IMMUNITY 
A. Introduction 
Autologous tumor cell vaccines (ATCVs) have been widely investigated for the past few years 
for their ability to prevent cancer recurrence (1-3). ATCVs are generated by deriving malignant 
cells from patient’s own tumor, that are processed and administered to initiate a tumor specific 
immune response. Since the malignant cells are isolated from self, ATCVs are HLA-matched 
and can facilitate a polyclonal tumor specific immune response. Additionally, unlike peptide 
based vaccines, ATCVs do not require pre-antigen selection. Thus, in heterogeneous cancers 
such as breast carcinoma, the ability of ATCVs to present all tumor associated antigens (TAAs) 
makes it highly likely to be a successful clinical strategy (4-6). Additionally, autologous vaccines 
open the possibility of treating triple negative breast cancer (TNBC), an extremely aggressive 
breast cancer type that lacks hormone and HER2 receptors which are otherwise the usual targets 
in breast cancer therapy (7).  
However, despite being a promising strategy in breast cancer treatment, ATCVs suffer from a 
major drawback. Cancer cells isolated from patients, often tend to be poorly immunogenic, 
thereby lacking the ability to activate the immune system (8). The poor immunogenicity of the 
isolated cancer cells is unavoidable, since the malignant cells that survive and expand in the body 
are the ones that have developed mechanisms to evade the immune system (8). Generally, 
malignant cells escape immunosurveillance by downregulating the expression of major 
histocompatibility complex (MHCI/II) or other costimulatory molecules such as B7-1 and B7-2 
(9). Hence, several studies are under investigation to enhance the immunogenicity of autologous 
cells by improving their expression of these costimulatory molecules. The most commonly used 
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method involves the use of cytokines such as interferons, GM-CSF or IL-12 to upregulate the 
expression of MHCII and B7-1 (4, 10). Another strategy is to genetically modify cancer cells to 
make them more immunogenic (11).  
However, clinical success so far, in ATCV based vaccines have only been in naturally more 
immunogenic cancers such as melanoma or non-small cell lung cancer. On the other hand, for 
non-immunogenic cancers, they are usually tested only as a combination therapy along with 
checkpoint inhibitors (12). Thus, understanding the reason for the poor immunogenicity of non-
immunogenic tumors, is a requirement for their successful clinical translation.  
Thus, in this study, we set out to determine the reasons for the poor immunogenicity of ATCVs 
against breast cancer. To do this, we are using two murine breast cancer cells, 4T1 and EMT6, 
varying in their levels of metastatic ability. Here, 4T1 is highly aggressive and metastatic breast 
cancer model that imitates stage IV breast cancer in humans. On the other hand, EMT6 is 
comparatively less aggressive and non-metastatic breast cancer model (13, 14). 
B. Materials and methods 
Reagents 
Cell culture media components including Dulbecco’s modified eagle medium (DMEM), Roswell 
Park Memorial Institute-1640 (RPMI-1640) medium, fetal bovine serum (FBS) and 
penicillin/streptomycin were purchased from Hyclone laboratories (Marlborough, MA). 
Ammonium-chloride-potassium (ACK) buffer used in the lysis of red blood cells while isolating 
splenocytes, was purchased from Lonza (Allendale, NJ). All fluorochrome-conjugated antibodies 
used in the study were purchased from BD Biosciences (San Jose, CA).       
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Mice  
All experimental procedures were approved by the Institutional Animal Care and Use Committee 
at University of Arkansas. Female Balb/cByJ mice were purchased from The Jackson Laboratory 
(Bar Harbor, ME, USA) and were housed in microisolator cages. Mice were utilized for 
experiments at 8-12 weeks of age and animal care followed ‘The Guide for Care and Use of 
Laboratory Animals’ (National Research Council). 
Breast cancer cell lines 
Murine breast cancer cells, 4T1 and EMT6 were purchased from American Type Culture 
Collection (Manassas, VA, USA). The rest of the breast cancer cells, namely 4T07, 67NR, 
66Cl4, 168 FARN were a generous gift from Dr. Fred Miller, Karmanos Cancer Institute, 
Detroit, MI. All cell lines except EMT6 were maintained in DMEM supplemented with 10% 
FBS and 1% penicillin/streptomycin. On the other hand, EMT6 cells were maintained in RPMI 
supplemented with 15% FBS and 1% penicillin/streptomycin. All cell cultures were maintained 
at 37˚C in a humidified CO2 incubator with 5% CO2. 
CRISP/Cas9 genome deletion of G-CSF 
Using the CRISPR design tool provided by Zhang lab (MIT, Cambridge, MA) a 20bp guide 
sequence targeting the granulocyte colony stimulating factor (G-CSF) gene in 4T1 cells was 
identified. Guide sequences were cloned into separate pCas-Guide-EF1a-GFP plasmid via 
Origene’s cloning service. Plasmids were amplified in E. coli and isolated via QIAGEN Plasmid 
Maxi Kit. For transfection, plasmid encoding gRNA (10ug) was mixed with Lipofectamine 3000 
reagent and added to 1x106 4T1 cells, that were pre-seeded on a 6 well plate 24 hours prior to 
transfection. 24-48 hours after transfecting, the cells that expressed GFP signal were sorted using 
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FACSAriaIII system (BD Biosciences). Sorted cells were subsequently cloned via limiting 
dilution. Further, by using G-CSF specific ELISA kit from R&D systems Inc. (Minneapolis, 
MN), clones producing lower than detectable levels of G-CSF were identified and used in 
experiments as 4T1.GCSF-KO. 
Prophylactic vaccine studies  
Tumor cell vaccines were generated by irradiating 4T1 or EMT6 cells at 100Gy using a 
Gammacell 1000 cesium irradiator. Mice were subcutaneously vaccinated with a primary and 
booster vaccine, 10 days apart with 1x106 irradiated 4T1 cells (4T1 vaccine) or 5x105 irradiated 
EMT6 cells (EMT6 vaccine). On the other hand, for ipsilateral and contralateral hybrid vaccines, 
1x106 irradiated 4T1 cells and 5x105 irradiated EMT6 cells were injected on the same and 
opposite flanks, respectively. In some instance, 4T1.G-CSF KO cells were used in place of 4T1 
cells. Vaccinated mice were challenged with 5x105 4T1, EMT6 or 4T1.G-CSF KO cells, 10 days 
after the booster vaccine. Tumor volumes were recorded 2-3 times per week using the formula 
V= (WxWxL)/2, where V is tumor volume, W is tumor width and L is tumor length.  
In-vitro cytokine analysis  
5x105 4T1 or EMT6 cells were seeded on a T25 flask and cultured for 48 hours. Cell culture 
supernatants were collected and centrifuged to remove any non-adherent cells and stored at -
80°C until analysis. Levels of cytokines monocyte-colony stimulating factor (M-CSF) and 
vascular endothelial growth factor (VEGF) in the cell culture supernatant were quantified via 
enzyme-linked immunosorbent assay kits (ELISA) from R&D systems Inc. (Minneapolis, MN). 
Whereas, transforming growth factor-β (TGF-β) was analyzed using latent TGF-β ELISA kit 
from Biolegend (San Diego, CA). On the other hand, cytokines interleukin-6 (IL-6), monocyte 
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chemotactic protein (MCP-1), GM-CSF and G-CSF were analyzed via cytometric bead array 
(CBA) on a FACSCantoII from BD Biosciences.   
G-CSF in sera from mice 
Blood from mice bearing 4T1, 4T1.GCSF-KO, 4T07, 67NR, 168FARN and 66Cl4 were 
collected in microcentrifuge tubes, when the tumor volume reached about 500-700mm3. The 
blood samples were left at room temperature for 10-15 minutes and then centrifuged at 4000 rpm 
for 30 minutes. The sera were then carefully collected using a micropipette and tested for the 
levels of G-CSF using G-CSF specific ELISA kit from R&D systems Inc. (Minneapolis, MN).   
Expression of MHC and costimulatory molecules 
Irradiated and non-irradiated 4T1 and EMT6 cells (5x105 cells) were stained with fluorochrome-
conjugated anti-CD80, anti-CD86, anti-H2-Kb (MHC I), anti-I-Ad/I-Ed (MHC II), anti-CD54 
(ICAM-1) and anti-CD95 (FasR). The labeled and unlabeled cells were analyzed on a FACS 
Canto II. The differences in median fluorescence intensity (ΔMFI) between unstained and 
stained cells were determined using FlowJo software (Tree Star, San Carlos, CA).   
Tissue collection and analysis of immune cell subsets 
Spleens and draining lymph nodes (DLN) from 4T1 and 4T1.GCSF-KO tumor bearing mice 
were isolated when tumors reached a volume of about 500-700 mm3. Single cell suspensions 
were prepared by mechanically dissociating both spleen and DLN samples and filtering through 
a 40µm nylon mesh cell strainer. Splenocytes were additionally treated with ACK buffer for 10 
minutes to lyse red blood cells. Single cell suspensions were then blocked with purified rat anti-
mouse CD16/CD32 monoclonal antibody (BD Biosciences, San Jose, CA) and stained with 
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fluorochrome-conjugated anti-CD11b, anti-CD19, anti-Ly6G and Ly6C, anti-CD3ε, anti-CD25 
and anti-CD4 for 40 minutes at 4˚C. Cells were then rinsed, fixed and permeabilized with 1x 
perm/wash buffer from BD biosciences. The permeabilized cells were further incubated with 
fluorochrome-conjugated anti-FoxP3 for 40 minutes. The samples were then read on a BD FACS 
Canto II flow cytometer. Further, using FlowJo software, frequencies of myeloid derived 
suppressor cells (MDSCs), T cells, B cells and regulatory T cells (Tregs) were determined. For 
mice bearing 4T07, 67NR, 66Cl4 and 168FARN tumors, only the frequency of MDSCs in spleen 
were determined.    
Statistical analysis 
All data were analyzed using GraphPad Prism software, version 7 (La Jolla, CA). For all in vivo 
vaccine studies, Kaplan Meier survival curves were plotted and the comparisons were made 
using log rank test. For all other studies, the data is represented as mean ± standard error and the 
comparisons were made using ANOVA followed by Tukey’s or Dunnett’s posttest.  
C. Results 
4T1 cells are poorly immunogenic while EMT6 cells are moderately immunogenic  
A standard prophylactic vaccine model was used to evaluate the immunogenicities of 4T1 and 
EMT6 breast cancer cell lines. Mice were vaccinated with irradiated 4T1 or EMT6 cells and 
challenged with live 4T1 or EMT6, respectively. As expected, vaccinated mice exhibited 
extended survival when compared to unvaccinated controls. However, when looking at the 
percentage of mice that remained tumor free, 70% of EMT6 vaccinated mice did not develop any 
tumor upon live EMT6 challenge. On the other hand, all 4T1 immunized mice developed tumors, 
upon live 4T1 challenge (Figure 1).   
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Costimulatory molecule and MHC expression on breast cancer cell lines  
The elaboration of robust adaptive immunity requires antigen presentation in MHC I or MHCII 
complexes (signal 1) and simultaneous engagement of costimulatory molecules, such as B7-1, 
B7-2, ICAM-1 and FasR, on APCs, with their cognate receptors, T cell receptor (TCR), CD28, 
lymphocyte function-associated antigen1 (LFA-1) and Fas ligand (Fas-L) on lymphocytes. Thus, 
MHC and costimulatory molecules on 4T1 and EMT6 cells were evaluated to determine if 
differences in expression level could explain observed differences in immunogenicity. Since 
irradiated cells were found to naturally fluoresce more than non-irradiated cells, this was 
considered by comparing only the differences in mean fluorescence intensity (ΔMFI) between 
unstained and stained non-irradiated cells or unstained and stained irradiated cells (Table 1).  
MHC I and MHCII are molecules that are required for presenting intracellular antigens to CD8+ 
and CD4+ T cells, respectively (15). Prior to irradiation, both 4T1 and EMT6 cells expressed 
MHCI at similar levels. Upon irradiation, though the ΔMFI values increased for both 4T1 (32 ± 
11.3) and EMT6 (52.5 ± 9.19), there was no significant difference between the two cell lines. 
Likewise, the expression of MHCII molecules, that are required for presentation of antigen to 
CD4+ T cells (helper T cells) were comparable between the two cell lines before and after 
irradiation.  
B7-1 and B7-2 are costimulatory molecules that would bind with CD28 on T cells. This 
costimulation provides the second signal that is required for antigen specific T cell response (16). 
Though there was no significant difference in the ΔMFI values of B7-2 between 4T1 and EMT6 
cells before and after irradiation, EMT6 cells expressed higher levels of B7-1 upon irradiation. 
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Specifically, the ΔMFI of B7-1 for irradiated 4T1 cells was 38.2 ± 23, whereas it was 253 ± 1.3 
for irradiated EMT6 cells.  
ICAM-1 is a ligand for LFA-1, that is expressed on leukocytes. The high levels of expression of 
ICAM-1 would thus mean an increased level of transcellular migration of leukocytes to the 
tumor site. Additionally, ICAM-1 expression also acts as a costimulatory signal for CTL 
activation (17). Likewise, FasR is another costimulatory receptor, which when bound to Fas-L on 
CTLs, would cause apoptosis of the cell expressing FasR (15). Here, though there was no 
significant difference in the ΔMFI values of ICAM-1 between 4T1 and EMT6 before and after 
irradiation, the ΔMFI value of FasR for EMT6 cells was significantly higher than that of 4T1 
cells, both before and after irradiation. Specifically, ΔMFI of FasR for 4T1 cells were only 366.7 
± 30.6 and 1197.7 ± 177, when compared to 2393.75 ± 56.2 and 4913.05 ± 155 for EMT6 cells, 
before and after irradiation, respectively.   
Differences in cytokine release  
Another factor that could influence the immunogenicity of a tumor cell vaccine is its release of 
immunosuppressive cytokines. To this end, IL-6, VEGF, TGF-β, MCP-1 and colony stimulating 
factors G-CSF, M-CSF and GM-CSF secreted by 4T1 and EMT6, before and after irradiation 
were compared (Figure 2).  
Colony stimulating factors, G-CSF, GM-CSF and M-CSF in healthy individuals are known to 
initiate the proliferation and differentiation of immature myeloid cells. However, at higher levels, 
as is usually found in tumor microenvironment, these growth factors are associated with resulting 
in the expansion of immunosuppressive myeloid cells, known as MDSCs (18). We found that, all 
three colony stimulating factors were released by irradiated 4T1 cells were significantly higher 
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than irradiated EMT6 cells.    Most strikingly, the levels of G-CSF released by 4T1 cells before 
irradiation (5765 ± 80.9 pg/105 cells) and after irradiation (5334 ± 114.2 pg/105 cells) were 
exceptionally high when compared to the levels released by EMT6 cells before (1100 ± 98.84 
pg/105 cells) and after irradiation (1760 ± 145.1 pg/105 cells).  
In tumor microenvironment, IL-6 is known to play a key role in promoting cancer cell 
proliferation and metastatic dissemination. It is also known to extrinsically act on other cells 
within the microenvironment, to induce angiogenesis (19). Here, IL-6 was found to be released 
at higher levels before irradiation (4T1: 62.6 ± 8.4 pg/105 cells; EMT6: 25.6 ± 3.7 pg/105 cells). 
However, upon irradiation, there was no significant difference in IL-6 release between the two 
cell lines (4T1: 21.3 ± 1.8 pg/105 cells; EMT6: 44.3 ± 6.6 pg/105 cells). Likewise, tumor derived 
MCP-1 and VEGF are associated with promoting angiogenesis (20, 21). Additionally, VEGF has 
also been shown to initiate the generation of MDSCs from CD33+ mono-nuclear cells, in in-vitro 
studies (22). We found that 4T1 cells produce higher levels of MCP-1 only upon irradiation 
(4T1: 1596 ± 123.6 pg/105 cells; EMT6: 744.7 ± 58.91 pg/105 cells). On the contrary, EMT6 
cells produced higher levels of VEGF before (833 ± 41.19 pg/105 cells) and after (371.3 ± 8.09 
pg/105 cells) irradiation, when compared to 4T1 cells before (10 ± 1.1 pg/105 cells) and after (8.6 
± 0.6 pg/105 cells).  
Similarly, TGF-β, a cytokine known to promote the development of Tregs was produced at 
higher levels by EMT6 cells before irradiation (4T1: 108 ± 7.6 pg/105 cells; EMT6: 832 ± 49 
pg/105 cells). However, upon irradiation, the difference was not significant (4T1: 355 ± 22.1 
pg/105 cells; EMT6: 274 ± 17 pg/105 cells).  
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Local and systemic effects of 4T1 mediated immunosuppression  
Based on differences in cytokine release (Fig 2), we explored if immunosuppressive cytokines 
released by 4T1 cells would abrogate the protective immunity established by the irradiated 
EMT6 vaccine. To explore the effect of a local immune suppression, we made a heterogeneous 
mixture of irradiated 4T1 and EMT6 cells (ipsilateral hybrid vaccine) and injected it 
subcutaneously to mice. On the other hand, to explore a possible systemic immune suppression 
mediated by 4T1 cells, we vaccinated mice with irradiated 4T1 cells and EMT6 cells on opposite 
flanks (contralateral hybrid vaccine). When both groups of mice were challenged with live 
EMT6 cells, the tumor free survival in the ipsilateral and contralateral vaccine groups dropped to 
40% and 25% respectively. This suggested that the 4T1 cells in the vaccine have a systemic 
inhibitory effect on the immune response (Figure 3).   
The immunosuppressive role of G-CSF 
Due to the abnormally high levels of G-CSF produced by 4T1 cells with/without irradiation, we 
hypothesized that it plays a key role in inhibiting the efficacy of ipsilateral and contralateral 
vaccines. To test this hypothesis, we deleted the G-CSF gene via CRISPR/Cas9 genomic editing.  
4T1 cells before G-CSF gene knock out released 4550 ± 604 pg of G-CSF per 105 cells, whereas 
after G-CSF gene knock out, they only released 386 ± 31 pg/105 cells. Furthermore, by limiting 
dilution, we selected a 4T1 colony that released lower than detectable levels of G-CSF in-vitro 
(4T1.G-CSF KO). Thus, we verified lack of G-CSF secretion in vitro by 4T1.G-CSF KO cells 
(Figure 4 a).  
Further, to verify lack of G-CSF in-vivo in mice bearing 4T1.G-CSF KO tumors, we measured 
the G-CSF serum concentration when the tumor volume reached about 500-700 3. We found that 
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4T1.G-CSF KO bearing mice had only 10 ± 2.9 pg/ml of G-CSF, which was comparable to G-
CSF in serum of naïve mice (59 ± 34 pg/ml). On the other hand, mice with comparable volume 
of 4T1 tumors, had 13096 ± 1947 pg/ml G-CSF (Figure 4 b). Additionally, we also isolated 
spleen and DLN from 4T1 and 4T1.G-CSF KO tumor bearing mice and determined the 
frequency of T cells, B cells, MDSCs and Tregs in the tissue samples. Here, we were specifically 
interested in MDSCs which are immature myeloid cells that have often been associated with high 
levels of colony stimulating factors (23, 24). Firstly, when the spleens were isolated, extreme 
splenomegaly was observed in spleens collected from 4T1 bearing mice (Figure 5). Secondly, we 
found that the spleen of 4T1 tumor bearing mice had significantly higher levels of MDSCs when 
compared to spleen from 4T1. G-CSF KO mice (4T1: 213 ± 21 MDSCs; 4T1.G-CSF KO: 26 
±10 MDSCs) (Figure 6 a). Similarly, 4T1 tumor bearing mice also had significantly higher 
numbers of T cells, B cells and Tregs, when compared to 4T1.G-CSF KO tumor bearing mice. 
(4T1: 82 ± 8 T cells, 37 ± 8 B cells and 4 ± 0.5 Tregs; 4T1.G-CSF KO: 28 ± 7 T cells, 14 ± 3 B 
cells and 1.5 ± 0.5 Tregs) (Figure 6 b, c and d). Additionally, the levels of all four cell types in 
4T1.G-CSF KO were comparable with the levels in naïve mice.  
Likewise, when the DLNs were analyzed, there was significant difference in the number of T 
cells between 4T1 and 4T1.G-CSF KO, whereas the levels were similar in 4T1.G-CSF KO and 
naïve mice (4T1: 335 ± 81 cells; 4T1.G-CSF KO: 194 ± 42 cells; 45 ± 5 cells) (Figure 7 b). 
However, when we compared the number of MDSCs, all three groups were significantly 
different from one another (4T1: 35 ± 0.5 cells; 26 ± 3.5 cells; naïve 1.2 ± 0.3 cells) (Figure 7 a). 
However, interestingly, the 4T1.G-CSF KO group had slightly higher number Tregs when 
compared to mice of 4T1 and naïve group (Figure 7 d). Additionally, 4T1 (35 ± 0.5 cells) and 
4T1.G-CSF KO (26 ± 2 cells) mice had higher number of B cells, when compared to naïve mice, 
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which did not have any B cells. However, the difference was not statistically different (Figure 7 
c).   
Tumor associated G-CSF secretion correlates with MDSC accumulation in different breast 
cancers 
To further establish the correlation between tumor secreted G-CSF levels and MDSC 
accumulation, we implanted mice with different breast cancer cell lines, namely 4T07, 67NR, 
66Cl4 and 168 FARN, that are 4T1 sister cell lines that share a common origin (single, 
spontaneously arising breast tumor in balb/c mice), but different in their metastatic ability. 4T1 
metastasizes to lung, liver, brain and bone; 66Cl4 to only lungs and liver and 168 FARN does 
not metastasize beyond the lymph nodes. While, 67NR are non-metastatic, 4T07 cells are 
frequently found in blood and lungs, but do not develop any visible metastatic nodules (25).  
We implanted each of these tumors in mice and measured the G-CSF in serum of mice when the 
tumor volumes were comparable (500-700mm3). We found that these cell lines release varying 
levels of G-CSF. 4T1 and 4T07 bearing mice had the highest levels of serum G-CSF, 19100 ± 
2274 pg/ml and 17600 ± 10220 pg/ml, respectively. On the other hand, 67NR, 66Cl4 and 
168FARN bearing mice had 165 ± 53 pg/ml, 117 ± 16 pg/ml and 46 ± 6 pg/ml, of serum G-CSF 
respectively, which were not significantly different from G-CSF in serum of naïve mice (59 ± 34 
pg/ml) (Figure 8 a).   
Thus, to determine the correlation between serum G-CSF levels and frequency of MDSCs, we 
determined the number of MDSCs in the spleen of the tumor bearing mice. We found that, 4T1 
and 4T07 tumor bearing mice had 1.27± 0.1 x108 and 1.9 ± 0.3 x108 MDSCs, respectively. These 
levels were significantly different from the number of MDSCs in the other three breast cancer 
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bearing mice (67NR: 4 ± 0.4 x106; 66Cl4: 3 ± 0.2 x106; 168FARN: 5 ± 0.7 x106 MDSCs) 
(Figure 8 b).     
Effect of G-CSF secretion on protective immunity 
From the above studies, we hypothesized that the high levels of G-CSF released by 4T1 cells in 
the vaccine were responsible for the poor immune response. To test this hypothesis, we repeated 
the contralateral hybrid vaccine study with irradiated 4T1.GCSF-KO plus EMT6 cells followed 
by a live EMT6 challenge. We found that in mice with vaccines containing 4T1.GCSF-KO cells, 
only 30% developed tumors. This was significantly different from contralateral vaccine with 4T1 
and EMT6 cells, where 70% of the mice developed EMT6 tumors (Figure 9). Additionally, we 
recorded survival in mice that were vaccinated and challenged with 4T1 or 4T1.G-CSF KO cells 
alone. We found that in the 4T1 group, all mice developed tumors, like the control group (naïve 
mice with 4T1 challenge). On the other hand, none of the mice in the 4T1.G-CSF KO vaccine 
group developed tumors (Figure 10).   
D. Discussion 
It is well established that ATCVs comprised of poorly immunogenic tumor cells are not 
effective. Thus, in this study, we set out to determine the reason for poor immunogenicity against 
breast cancer ATCVs by using two murine breast cancer cells, 4T1 and EMT6. Here, 4T1 is 
inherently non-immunogenic when compared to EMT6 cells, and therefore, we aim at 
understanding the reasons for differences in immunogenicities by studying their immune 
response.  
We initially confirmed the differences in ATCV response by vaccinating mice with irradiated 
4T1 or EMT6 cells and subsequently challenging with live 4T1 or EMT6 cells. We found that 
the ATCV against the immunogenic EMT6 cells developed protective immunity to live EMT6 
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challenge. On the other hand, 4T1 vaccine failed to provide any protective immunity (Figure 1). 
Thus, to determine the reasons for the differences in immunogenicities, we first looked at the 
levels of expression of immunologically relevant surface molecules MHC I, MHC II, B7-1, B7-
2, ICAM-1 and FasR, that would determine the robustness of T cell activation. We found that 
irradiated EMT6 cells express significantly higher levels of B7-1 and FasR, which could be 
responsible for the enhanced immune response to EMT6 vaccine (Table 1). However, when we 
studied the differences in some of the immunosuppressive cytokines released by these cells, we 
found that irradiated 4T1 cells release very high levels of GM-CSF, G-CSF and M-CSF (Figure 
2).  
Thus, to determine if the immunosuppression associated with 4T1 cells is ruining the vaccine 
response, we immunized mice with ipsilateral and contralateral hybrid vaccines and challenged 
them with live EMT6 cells. We found that the presence of irradiated 4T1 cells ruined the 
protective immunity to EMT6 challenge in both vaccine groups, implicating a systemic 
immunosuppressive response to irradiated 4T1 cells.  
Of the different immunosuppressive cytokines released by 4T1 cells, we noticed that G-CSF is 
released at exceptionally high levels when compared to the release by EMT6 cells. At such high 
levels, G-CSF and other colony stimulating factors have been previously associated with 
expansion of MDSCs in-vivo (18). Thus, in our study, to determine if G-CSF is resulting in 
expansion of MDSCs, we knocked out G-CSF in 4T1 cells (4T1.G-CSF KO) and implanted it to 
mice. We compared the levels of MDSCs in spleen and DLN of mice with 4T1 or 4T1.G-CSF 
KO tumors (of comparable tumor volume). We found that mice with 4T1 tumors had increased 
frequencies of MDSCs in both spleen and DLN, when compared to mice with 4T1.G-CSF KO 
tumors. We further established the correlation between tumor derived G-CSF and frequency of 
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MDSCs by using breast cancer cells releasing varying levels of G-CSF (4T07, 67NR, 66Cl4 and 
168 FARN).  
Additionally, to determine if the tumor derived G-CSF is responsible for abrogating vaccine 
efficacy, we utilized 4T1.G-CSF KO cells in the contralateral vaccine group. We found that 
immunizing with G-CSF KO vaccine improved the percentage of tumor free survival. Thus, the 
findings from this study established a causal link between tumor-derived G-CSF and a loss of 
autologous tumor cell vaccine response. However, it is important to note that our findings do not 
eliminate the possibility of other mechanisms that could be involved in MDSC expansion. For 
instance, knocking out other colony stimulating factors such as GM-CSF could have a similar 
effect on vaccine efficacy.  
For the first time, our study has completely knocked down G-CSF using CRISPR-Cas9 genome 
editing and established the relationship between tumor derived G-CSF and MDSC expansion. 
Additionally, by using other murine breast cancer cells of common origin, but naturally different 
levels of G-CSF secretion, we further confirmed that G-CSF is a key initiator in MDSC 
expansion. The findings from our study, agree with another study by Abrams et al, where the 
causal link between tumor derived G-CSF and splenic G-MDSC frequency was established (26). 
However, Abrams and group used RNA interference and transfection of cancer cells with G-CSF 
expression plasmid, to establish the correlation.  Recently, in a clinical study involving breast 
cancer patients, high G-CSF expression was found in the tumors of patients with the more 
aggressive forms of breast cancer and significantly correlated with poor overall survival (27). 
With the findings from our study, we now know that the poor overall survival in these patients 
with aggressive cancers, could very well be due to the MDSC associated immunosuppression. 
 35 
 
Additionally, our findings also imply that autologous vaccines against aggressive breast cancers, 
could be improved by targeting the tumor derived G-CSF expression.   
E. Conclusion 
Despite the plethora of studies on autologous tumor cell vaccines for heterogenous and non-
immunogenic cancers, the clinical outcome has been extremely poor. This failure in developing 
an effective vaccine is often linked to the inherent poor immunogenicity of the autologous cancer 
cells. In this study, we used two murine breast cancer cells, 4T1 (metastatic) and EMT6 (non-
metastatic), that are on the opposite sides of the spectrum of metastatic ability. We found that the 
ATCV against 4T1 was significantly ineffective when compared to EMT6.  
Therefore, by comparing the immune response against 4T1 and EMT6 ATCV, we found that 
4T1 cells release exceptionally high levels of G-CSF, when compared to EMT6. By eliminating 
G-CSF in these cells using CRISPR/Cas9 genome editing, we found that such high levels of G-
CSF result in the accumulation of immunosuppressive MDSCs in spleen and draining lymph 
nodes. Further, the findings established a causal link between tumor derived G-CSF and poor 
immunogenicity of ATCVs against breast cancer. We also successfully reestablished the 
correlation between tumor derived G-CSF and MDSC accumulation by using four different 4T1 
sister cell lines that naturally produced varying levels of G-CSF.  
The findings from this study, thus established the need to quantify the levels of serum G-CSF 
before generating an ATCV against breast cancer, that can be used as an indicator to determine 
the overall efficacy of the vaccine. Also, our findings show that future studies that target MDSC 
populations in breast cancers, could improve the overall survival.   
 
 36 
 
F. Tables and figures 
Table 1. Difference in expression of MHC and costimulatory molecules in non-irradiated 
and irradiated breast cancer cells. 4T1 and EMT6 cells were exposed to 0 or 100 Gray. 24 
hours after irradiation, cells were harvested and stained with fluorochrome conjugated anti-
CD80, anti-CD86, anti-H2-Kb, anti-I-Ad/I-Ed, anti-CD54 and anti-CD95. The samples were 
analyzed on a FACSCantoII. The differences in mean fluorescence intensities between unstained 
and stained non-irradiated cells; and unstained and stained irradiated cells were tabulated. The 
experiment was repeated thrice and the results were represented as mean fluorescence intensity ± 
standard error. 
 
Cells B7-1 B7-2 ICAM-1 MHCI MHCII FasR 
Non-
Irradiated 
4T1 5 ± 0.8 
22.75 
± 7.9 
13.25± 
6.8  
19.1 ± 
6.6 
31.9 ± 
13.5 
366.7 ± 
30.6 
EMT6 
38.2 ± 
23 
45.6 ± 
35.4 
16.75 ± 
6 
19.2 ± 
7.3 
60.8 ± 
45.7 
2393.75 
± 56.2 
Irradiated 
4T1 
11.05 
± 1.6 
45.3 ± 
4.6 38 ± 8.4 
32 ± 
11.3 
117.3 
± 28.7 
1197.7 ± 
177 
EMT6 
253 ± 
1.3 
77.5 ± 
19.9 
19.5 ± 
10.6 
52.5 ± 
9.19 
135 ± 
39 
4913.05 
± 155 
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Figure 1. Differences in protective immunity induced by irradiated breast cancer cell lines. 
Balb/cByJ mice received 1x106 irradiated 4T1 cells (4T1 vaccine) or 5x105 irradiated EMT6 
cells (EMT6 vaccine) twice, 10 days apart. 10 days after booster vaccination, mice were 
challenged with live 5x105 4T1 or EMT6 cells, respectively. Additionally, naive mice that 
received only 5x105 live EMT6 cells (EMT6 control) or live 4T1 cells (4T1 control), served as 
controls for each group. Tumor growth was monitored and mice were sacrificed when the tumor 
volumes reached about 2000mm3. Kaplan-Meier curves were plotted for mice of the above 
groups (**p<0.01, *p<0.05). 
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Figure 2. Cytokine release profile of 4T1 and EMT6 cells before and after irradiation. 4T1 
or EMT6 cells were irradiated at 100Gy using a Gammacell irradiator. 5x105 non-irradiated 
(4T1 and EMT6) and irradiated (4T1 Irr and EMT6 Irr) cells were seeded on separate T25 
flasks and cultured for 48 hours. The cell media were collected from each flask and centrifuged 
to obtain cell-free supernatants. Levels of cytokines IL-6 (a), GM-CSF (b), MCP-1 (c) and G-
CSF (d) in the cell free supernatant were measured using cytometric bead array. Whereas, 
cytokines M-CSF (e), VEGF (f) and TGF-β (g) were measured via ELISA. The experiment was 
repeated thrice and the results represent mean± standard error (**p<0.01, *p<0.05).  
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Figure 3. 4T1 vaccine abrogates EMT6 immunity. Female balb/cByJ mice were vaccinated 
with irradiated 5x105 EMT6 cells (EMT6 vaccine) or homogenous mixture of irradiated 5x105 
EMT6 and 1x106 4T1 cells (ipsilateral hybrid vaccine) or irradiated 1x106 4T1 and 5x105 EMT6 
on opposite flanks (contralateral hybrid vaccine) twice, 10 days apart. Additionally, naïve mice 
that only received 5x105 EMT6 cells served as control. 10 days after the booster vaccine, all 
mice were challenged with live 5x105 EMT6 cells on the same side as the irradiated EMT6 cells.   
Tumor growth was monitored and mice were sacrificed when the tumor volume reached about 
2000mm3. Kaplan-Meier curves were plotted for mice of the above groups (**p<0.01). 
 
 
Figure 4. In-vitro and in-vivo G-CSF concentration. Female balb/cByJ mice were 
subcutaneously injected with 5x105 4T1 (n=5) or 4T1.GCSF-KO cells (n=5). The tumor growth 
was monitored and the serum samples were collected when the tumors reached 500-700mm3. 
Serum from naïve mice were collected to serve as control. Levels of G-CSF in the collected 
samples where measured via G-CSF specific ELISA. **p<0.01. 
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Figure 5. Extreme splenomegaly in spleen of 4T1 bearing mice. 1x106 4T1 or 4T1.G-CSF KO 
cells were subcutaneously injected to balb/cByJ mice. Mice were sacrificed and their spleens 
were isolated when the tumor volume reached about 500-700mm3. Spleen from mice bearing 
4T1 (1) or 4T1 KO (2) tumors compared with spleen from naïve mouse (3).  
     
 
 
 
  
 
 
 
 
 
 
 
 
Figure 6. Comparison of immune cell subsets in the spleen of 4T1 and 4T1.G-CSF KO 
bearing mice. 1x106 4T1 or 4T1.G-CSF KO cells were subcutaneously injected to balb/cByJ 
mice (n=3). Once tumors reached a volume of 500-700mm3, spleens were harvested and single 
cell suspensions obtained. Splenocytes isolated from naïve mice served as control (n=3). Cells 
were stained with fluorochrome-conjugated antibodies against CD3, CD4, CD25, FoxP3, 
CD11b, Ly6G and Ly6C and CD19. Flow cytometric analysis was performed to determine the 
percentage of MDSCs (CD11b+ and Ly6G and Ly6C+), B cells (CD19+), T cells (CD3+) and 
regulatory T cells (CD3+, CD4+, CD25+ and FoxP3+).  Absolute numbers of MDSCs (a), T 
cells (b), B cells (c) and Tregs (d)were calculated and the results are represented as mean ± 
standard error (n=3, **p<0.01, *p<0.05).  
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Figure 7. Comparison of immune cell subsets in the draining lymph nodes of 4T1 and 
4T1.G-CSF KO bearing mice. 1x106 4T1 or 4T1.G-CSF KO cells were subcutaneously 
injected to balb/cByJ mice (n=3). Once tumors reached a volume of 500-700mm3, draining 
lymph nodes were harvested and single cell suspensions obtained. Draining lymph nodes isolated 
from naïve mice served as control (n=3). Cells were stained with fluorochrome-conjugated 
antibodies against CD3, CD4, CD25, FoxP3, CD11b, Ly6G and Ly6C and CD19. Flow 
cytometric analysis was performed to determine the percentage of MDSCs (CD11b+ and Ly6G 
and Ly6C+), B cells (CD19+), T cells (CD3+) and regulatory T cells (CD3+, CD4+, CD25+ and 
FoxP3+).  Absolute numbers of MDSCs (a), T cells (b), B cells (c) and Tregs (d)were calculated 
and the results are represented as mean ± standard error (n=3, **p<0.01, *p<0.05).  
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Figure 8. Concentration of G-CSF in sera and number of MDSCs in spleen of mice bearing 
different breast cancer cell lines. Balb/cByJ mice were subcutaneously injected with 1x106 4T1 
cells (n=5), 5x106 4T07 cells (n=3), 1x106 168 FARN (n=3), 1x106 67 NR (n=5) and 3x106 
66Cl4 (n=5). When the tumor volumes reached 500mm3, blood samples were collected via 
submandibular bleeding and centrifuged at 4000 rpm for 30 minutes to isolate sera. The 
concentration of G-CSF in sera were determined via G-CSF specific ELISA kit (a). Also, mice 
were sacrificed following submandibular bleeding, the splenocytes were isolated and single cell 
suspensions obtained. Cells were stained for MDSCs using fluorochrome-conjugated anti-CD11b 
and anti-Ly6G and Ly6C and flow cytometric analysis was performed to determine absolute 
number of MDSCs (b). Results are represented as mean ± standard error (**p<0.01, *p<0.05).   
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Figure 9. Contralateral vaccine with irradiated 4T1.G-CSF KO cells has improved vaccine 
efficacy. Balb/cByJ mice received 5x105 irradiated EMT6 cells or 5x105 irradiated EMT6 cells 
and 1x106 irradiated 4T1 cells on opposite sides (contralateral vaccine with 4T1) or 5x105 
irradiated EMT6 cells and 1x106 irradiated 4T1.G-CSF KO cells on opposite sides (contralateral 
vaccine with 4T1.G-CSF KO) twice, 10 days apart. 10 days after booster vaccination, mice of 
the above groups were challenged with live 5x105 EMT6 cells. Additionally, naive mice that 
received only 5x105 live EMT6 cells, served as control. Tumor growth was monitored and mice 
were sacrificed when the tumor volume reached about 2000mm3. Kaplan-Meier curves were 
plotted for mice of each group (**p<0.01).  
 
 
Figure 10. Protective immunity to 4T1.G-CSF KO tumor. Balb/cByJ mice were vaccinated 
with 1x106 4T1 cells or 1x106 4T1.G-CSF KO cells, twice 10 days apart. 10 days after booster 
vaccination, the two groups of mice were challenged with live 5x105 4T1 cells or 5x105 4T1.G-
CSF KO cells, respectively. A third group contained naïve mice that received only a live 
challenge with 5x105 4T1 cells, served as control. Tumor growth was monitored and mice were 
sacrificed when the tumor volume reached about 2000mm3. Kaplan-Meier curves were plotted 
for mice of each group (**p<0.01).   
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IV. COMPARISON OF DIFFERENT TLR AGONISTS ON REVERSING MDSC 
ASSOCIATED IMMUNOSUPPRESSION  
A. Introduction 
Myeloid derived suppressor cells (MDSCs), a population of immature myeloid cells, play a 
crucial part in the efficacy of cancer vaccines (1). In healthy individuals, immature myeloid cells 
arise in the bone marrow and differentiate into mature leukocytes namely, granulocytes, dendritic 
cells and macrophages. However, in the presence of cancer, these cells are prevented from 
differentiation, resulting in a heterogenous population of immature myeloid cells, collectively 
termed as MDSCs (2). In mice, these cells are identified by their expression of Gr1 and CD11b 
and include two unique subsets, namely monocytic MDSCs (M-MDSCs) and granulocytic 
MDSCs (G-MDSCs). Here, G-MDSCs are Gr1high, Ly6G+ and Ly6Clow, whereas M-MDSCs are 
Gr1intermediate, Ly6Glow and Ly6Chigh (M-MDSCs) (3). In humans MDSCs express CD11b, CD33 
and low levels of human leukocyte antigen -antigen D related (HLADR). Further, G-MDSCs are 
CD33+Lin- and M-MDSCs are CD14+ HLA-DRlow/- co-receptorlow/- (4).  
MDSCs create an immune suppressed tumor microenvironment via multiple methods that 
include releasing immunosuppressive factors, cytokines and chemokines. The MDSC based 
immunosuppression mainly targets CD8+ T cell response by releasing extremely high levels of 
arginase and nitric oxide. These molecules in turn, collectively cause the depletion of arginine, 
that is required for T cell activation and function (5). Additionally, it was also found that MDSCs 
inhibit natural killer (NK) cell responses by decreasing macrophage associated IL-12 release. 
This in turn results in poor stimulation of NK cells, which are immune cells of the innate system 
that have the potential to kill cancer cells without prior sensitization (2, 6, 7). Simultaneously, 
MDSCs also release high levels of IL-10 that affect the maturation of dendritic cells which are 
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involved in antigen presentation (8). Also, M-MDSCs increase the number of regulatory T cells 
(Tregs), another immunosuppressive immune cell subset (3). Thus,  elevated levels of 
accumulation of MDSCs and their presence in peripheral blood are frequently associated with 
poor prognosis in cancer patients (9-11). 
Therefore, in the recent past, several approaches have been explored to eradicate MDSC 
associated immunosuppression (12). Different therapeutic agents such as IL-12, all trans-retinoic 
acid, vitamin A, etc. have been investigated for their ability to cause MDSC differentiation and 
improve survival via enhanced T cell response (2, 13).  
However, in 2007, for the first time it was found that MDSCs expand through signaling via 
MyD88, an adaptor required for toll like receptor (TLR) signaling (14). TLRs are type I 
membrane glycoproteins, that play an important role in innate immunity. They are expressed on 
different immune cells such as B cells, macrophages, dendritic cells, as well as on non-immune 
cells such as endothelial and epithelial cells. So far, researchers have identified 10 and 13 TLR 
members in mice and human, respectively (15).     
Thus, after the effect of MyD88 signaling on MDSCs was determined, several researchers 
explored the effect of different TLR agonists (molecules that target TLRs) on MDSCs. Though, 
all agonists were expected to have a positive effect on MDSC expansion, researchers found that 
some agonists can initiate MDSC differentiation. For instance, while a study using LPS and IFN-
γ found that levels of expression of dendritic cells and macrophage markers (F4/80, CD11c, 
DEC205) remains unchanged (16), another study using Poly (I:C), a TLR 3 agonist reported an 
upregulation of maturation markers on these cells. Here, an intraperitoneal injection of Poly (I:C) 
into 4T1 tumor bearing mice, was found to decrease the frequencies of MDSCs in blood, bone 
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marrow and tumor when compared to mice treated with saline (17). However, when the effect of 
two different TLR agonists, Pam (TLR 1/2 agonist) and R848 (TLR 7/8 agonist) on M-MDSC 
differentiation were compared in another study, the results were contradicting. When M-MDSCs 
were isolated from human peripheral blood mononuclear cells (PBMCs) and treated with Pam or 
R848, Pam was found to differentiate M-MDSCs into M2-like macrophages, that are 
immunosuppressive. On the other hand, R848 differentiated M-MDSCs to M1-like macrophages, 
that are known to have tumoricidal properties (18).       
Thus, there is a need to understand the effect of different TLR agonists on MDSC differentiation. 
Expanded knowledge on the effect of these molecules would help develop immunotherapeutic 
strategies to improve efficacy of different cancer vaccines. Additionally, it would also help in 
reversing tumor associated immunosuppression, which is one of the major reasons for tumor 
recurrence in cancer patients (19).   
Therefore, this study aims at comparing the effect of different commercially available TLR 
agonists on the differentiation and immunosuppressive activity of MDSCs. Here, unlike most 
studies where MDSCs are isolated to test the effect of the agonist, we are looking at the overall 
response while the cells are in the whole splenocyte culture. By doing so, we believe that we can 
understand the overall immune response better, since the MDSCs are in an environment that 
closely mimics in-vivo events. Here, though we also tested for the effect of IL-12 on MDSC 
maturation in-vitro, we did not observe any significant effect. The results from this study can be 
found in the appendix section.  
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B. Materials and methods 
Reagents 
Pam3CSK4 (Pam), Poly (I:C)-LMW (Poly IC), FSL-1, FLA-ST and R848 were purchased from 
InvivoGen (San Diego, CA). All fluorochrome conjugated monoclonal antibodies (mAb) used in 
the detection of different immune cell subsets were purchased from BD Biosciences (San Jose, 
CA). Recombinant mouse granulocyte-monocyte colony stimulating factor (rGM-CSF) used in 
maintaining the viability of MDSCs in culture, were purchased from Sigma-Aldrich (St. Louis, 
MO).  
Cell culture media components including Dulbecco’s modified eagle medium (DMEM), Roswell 
Park Memorial Institute-1640 (RPMI-1640) medium, fetal bovine serum (FBS) and 
penicillin/streptomycin were purchased from Hyclone laboratories (Marlborough, MA). 
Ammonium-chloride-potassium (ACK) buffer used in the lysis of red blood cells while isolating 
splenocytes, was purchased from Lonza (Allendale, NJ).       
Cell culture 
4T1, murine breast cancer cells, were purchased from American Type Culture Collection 
(Manassas, VA, USA) and maintained in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin. Splenocytes from tumor bearing mice were isolated following the 
procedure described below. Isolated splenocytes were treated with 10ng/ml rGM-CSF and/or 
TLR agonists (at concentrations as mentioned in Table 1) in RPMI-1640 medium supplemented 
with 10% FBS and 1% penicillin/streptomycin. All cell cultures were maintained in a humidified 
CO2 incubator with 5% CO2 at 37˚C.  
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Mice 
Female Balb/cByJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) 
and were housed in microisolator cages. All experimental procedures were approved by the 
Institutional Animal Care and Use Committee at University of Arkansas. Mice were utilized for 
experiments at 8-12 weeks of age and animal care followed ‘The Guide for Care and Use of 
Laboratory Animals’ (National Research Council). 
Splenocyte isolation  
Mice were injected subcutaneously with 1x106 4T1 cells and tumor growth was monitored. 
Spleens from tumor bearing (500-700mm3) mice were isolated and single cell suspensions were 
prepared by mechanical dissociation. Further, the cell suspensions were passed through a 40µm 
nylon mesh before treating with ACK buffer, to lyse red blood cells. The cells were then washed 
and resuspended in PBS buffer for further analysis. 
Toll like receptor expression  
Isolated splenocytes were incubated with purified rat anti-mouse CD16/CD32 monoclonal 
antibody (BD Biosciences, San Jose, CA) for 10 at 4˚C, to block any non-specific binding of Fc 
receptors  This was followed by staining with fluorochrome-conjugated anti-mouse Ly6G and 
Ly6C, anti-mouse CD11b, anti-mouse TLR1, anti-mouse TLR2 and anti-mouse TLR4 from 
eBioscience (San Diego, CA); fluorochrome-conjugated anti-mouse TLR3 and anti-mouse TLR7 
from BD Biosciences (San Jose, CA); fluorochrome-conjugated anti-mouse TLR5 and anti-
mouse TLR8 from abcam (Cambridge, MA) and fluorochrome-conjugated anti-mouse TLR6 
from R&D systems (Minneapolis, MN). Cells stained with fluorochrome conjugated mouse IgG1 
kappa antibodies were used as isotype controls.  
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After subsequent wash and resuspension in PBS, the cells were acquired using BD FACS Canto 
II flow cytometer. Further, using FlowJo software, viable MDSCs were gated following the 
gating strategy as in Figure 3 and the expression of TLRs 1-8 by these cells were detected.  
Flow cytometry  
Using a cell scraper, adherent cells in splenocyte cultures treated with both concentrations of 
each TLR agonist (for 24 and 72 hours), were detached. The media containing non-adherent and 
adherent cells were collected, centrifuged and cell pellets obtained. Homogeneous single cell 
suspension of the cells was produced by resuspending the cells in PBS.  To block non-specific 
FC receptor mediated binding, the cells were first incubated with purified rat anti-mouse 
CD16/CD32 monoclonal antibody for 10 at 4˚C. Further, the cells were stained with fixable 
viability stain 660 for 15 minutes to detect viable cells. The cells were then washed and stained 
with fluorochrome-conjugated anti-CD11b, anti-Ly6G and Ly6C, anti-CD19, anti-CD3ε, anti-
CD25, anti-CD4, anti-CD80, anti-CD86, anti-I-Ad/I-Ed (MHCII) and anti-F4/80 for 40 minutes 
at 4˚C. This was followed by fixing and permeabilizing the cells using 1x fix/perm buffer from 
BD biosciences. The permeabilized cells were then incubated with fluorochrome-conjugated 
anti-FoxP3 for 40 minutes, washed and resuspended in PBS. The samples were then acquired 
using FACScantoII and the flow cytometric data was analyzed using FlowJo software. The 
number of myeloid derived suppressor cells (MDSCs), CD11c+ cells, T cells, B cells and 
regulatory T cells (Tregs) were determined. Further the levels of expression of CD80, CD86, 
MHCII and F4/80 by MDSCs were analyzed. The gating strategies for MDSCs, CD11c+ cells, T 
cells, B cells and Tregs are shown (Figure 3 and Figure 4).     
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Cytokine release study 
Cell culture media from splenocytes treated with the two different concentrations (low and high) 
of each TLR agonist for 24 and 72 hours were collected. The samples were then centrifuged to 
obtain cell free supernatants and the concentration of cytokines IL-6, IL-10 and TNF were 
detected using CBA. Further, concentration of TGF-β and IL-12 were detected via cytokine 
specific enzyme linked immunosorbent assay (ELISA).   
C. Results 
Expression of TLRs 1-8 by MDSCs 
Since we are testing for the effect of different TLR agonists on MDSCs, we first wanted to 
ensure the expression of the receptors by these cells. We found that all eight TLRs tested (TLRs 
1-8), were expressed by MDSCs (Figure 1). 
Effect of TLR agonists on MDSC maturation 
To determine the effect of TLR agonists on MDSC maturation, we treated splenocytes with 
rGM-CSF(10ng/ml) plus each of the TLR agonists at two different concentrations (Table 1). 
Here, GM-CSF was used to keep the splenocytes viable in culture and the concentrations of TLR 
agonists were selected such that the ‘low’ concentration represents the standard dose as found in 
the literature, whereas the ‘high’ is ten times the standard dose.  
We then gated for MDSCs in the culture and tested for the expression of common maturation 
markers namely, CD80, CD86, MHCII and F4/80 by these cells (Figure 2). Of all the TLR 
agonists, only Pam resulted in an increase in expression of all four maturation markers with 24 
and 72 hours of treatment. On the other hand, agonists LPS and FSL-1 resulted in upregulation 
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of CD80 and F4/80 alone with 24 and 72 hours of treatment. The effect was observed with both 
concentrations of the agonists LPS and FSL-1. R848 caused an increase in expression of MHCII 
and F4/80, only 72 hours after treatment. Poly IC and FLA-ST did not have any effect on MDSC 
maturation.     
Effect of TLR agonists on frequency of different immune cell subsets 
When we looked at cells treated with the TLR agonists under the microscope, we found some 
dendritic-like looking cells in some treatments. Hence, in addition to analyzing T cells, B cells, 
MDSCs and Tregs upon treatment, we also included antibodies against CD11c, a dendritic cell 
marker. 
Of all the agonists tested, only Pam and FSL-1 did not have any effect on the number of B cells, 
when compared to cells treated with rGM-CSF alone. All other agonists, significantly decreased 
the number of B cells at the 24-hour time point at both doses. Interestingly, the differences were 
no longer significant at the 72-hour time point, except for with R8484. The numbers of B cells in 
samples treated with the high dose of R848 significantly increased at the 72-hour time point 
(Figure 5, Figure 6). 
Further, looking at the number of T cells, at the lower dose, only LPS had a significant effect on 
the T cell population, 72 hours after treatment. However, at the higher dose, both LPS and Pam 
had a significant effect at 72 and 24-hour time points, respectively. Similarly, only Poly IC 
significantly decreased the number of CD11c+ cells at the 24-hour time point with both doses. 
We also found that of all the agonists, only Pam and FSL-1 resulted in a significant decrease in 
the number of MDSCs, when compared to cells treated with rGM-CSF alone. This effect was 
found at both doses of the agonists and at both time points. Though LPS also decreased the 
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number of MDSCs, the difference was significant only with the higher dose of LPS at 24-hour 
time point.  
Difference in cytokines released by splenocytes treated with TLR agonists 
To get an idea for the overall effect of each agonist on the immune response, we looked at the 
levels of different cytokines that are usually associated with tumorigenesis. We compared these 
levels with the levels of cytokines released by splenocytes treated with rGM-CSF alone (Figure 7 
and Figure 8). IL-6, a cytokine known to induce proliferation of cancer cells and inhibit their 
apoptosis, were found to be released at significantly higher levels by splenocytes treated with 
Pam, LPS and FSL-1 at both concentrations and at both time points. Splenocytes treated with 
R848 also released slightly higher levels of IL-6 at all treatment conditions, except with the low 
dose at the 24-hour time point. Similarly, IL-10, a cytokine involved in expansion of Tregs, was 
also found to be released at significantly higher levels by Pam, LPS, FSL-1 and R848. However, 
the differences were significant at all treatment conditions for all four agonists. 
On the other hand, Pam, LPS, FSL-1 and R848, at the lower dose resulted in a decrease in the 
levels of TGF-β, another cytokine associated with expansion of Tregs at the 72-hour time point. 
Whereas at the higher doses of agonists, Pam, LPS, FSL-1 and Poly IC caused a decrease in 
TGF-β levels at the 72-hour time point. Further, when we measured the levels of TNF with low 
doses of agonists, we again found that all agonists except FSL-1 released significantly higher 
levels of TNF. However, with the higher dose, FSL-1 also resulted in significantly higher levels 
of TNF. On the contrary, only cells treated with R848 released any detectable levels of IFN-γ 
and IL-12.  
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D. Discussion 
MDSCs are immunosuppressive immune cells of the myeloid lineage that expand aggressively in 
the presence of some cancers. The rapid accumulation of these cells in the tumor 
microenvironment facilitate tumor growth and progression. Additionally, their 
immunosuppressive activity could be a serious threat to newly developing cancer vaccines and 
immunotherapies.  
Researchers have investigated the use of a few TLR agonists such as LPS, R848 and Poly IC in 
differentiating or expanding these cells. However, the findings from these studies are 
contradicting, since not all agonists have similar effects on MDSC maturation. Therefore, we set 
out to compare the effect of different commercially available TLR agonists on the maturation of 
MDSCs in-vitro. 
In this study, instead of isolating the MDSCs, we observed the effect of TLR agonists on MDSC 
maturation, while the cells were in the whole splenocyte culture. This helped us to not just 
analyze the MDSCs, but also understand the effect on other immune cell subsets such as T and B 
cells. Additionally, we determined levels of different cytokines released in the splenocyte 
culture, which provided additional information on the overall immune response. Also, we believe 
that studying the MDSCs in the whole splenocyte culture would better mimic the in-vivo events.   
We found that, even though MDSCs express all eight TLRs (TLRs 1-8), not all agonists cause 
the maturation of MDSCs. When we looked at the expression of maturation markers CD80, 
CD86, MHCII and F4/80, we found that only Pam upregulated the expression of all four 
maturation markers, at both low and high concentrations. On the other hand, FSL-1 and LPS 
only upregulated CD80 and F4/80, whereas R848 only upregulated MHCII and F4/80. On the 
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contrary, FLA-ST and Poly IC did not have any effect on MDSC maturation as well as MDSC 
count. Additionally, when looking at the effect on the number of MDSCs, at the low 
concentration, only Pam and FSL-1 significantly decreased the number of MDSCs. However, at 
the higher concentration, LPS also significantly decreased MDSC levels.  
Our study, thus showed that Pam can initiate maturation of MDSCs and decrease the MDSC 
count in-vitro. However, this contradicted the findings by Wang et al. Here, Pam when co-
cultured with human M-MDSCs, increased the expression of CD200R and CD206, thereby 
increasing their immunosuppressive activity (18). Additionally, in our study we found Poly IC to 
have no effect on any of the four maturation markers on MDSCs. This contradicted the findings 
by Forghani et al, where MDSCs isolated from the spleen of 4T1 tumor bearing mice when co-
cultured with 20µg/ml of Poly IC resulted in upregulation of MHCII, CD80 and CD86 (17). 
However, it is important to note that in both studies, the effect on maturation were determined on 
isolated M-MDSCs or MDSCs. The different cytokines released by other immune cells in the 
culture and their interaction with MDSCs in our study, could be the rationale for the differences 
in MDSC maturation.  
In our study, though we also looked at the levels of other immune cells, such as T and B cells, 
the findings are preliminary. Additional experiments such as determining the frequency of 
regulatory B and T cells are required to understand the overall immune response.  
Additionally, we also looked at the concentration of different cytokines in splenocytes co-
cultured with the TLR agonists. Only cultures treated with Pam, Poly IC and LPS had 
significantly high levels of IL-6 and IL-10. Though these cytokines are usually associated with 
tumorigenesis, recent studies have revealed the dual role of both cytokines in tumor 
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microenvironment. IL-6 trans-signaling can attract lymphocytes to tumor and lymph nodes and 
activate them towards immunostimulatory phenotype (24). Similarly, growing evidence is 
revealing the role of IL-10 in T cell activation and tumor shrinkage (25). Additionally, we also 
found that splenocyte cultures treated with Pam, LPS, FSL-1 and R848 also had decreased levels 
of TGF-β. Per literature, TGF-β initiates the generation of Tregs, that are immunosuppressive 
and is a hindrance in the proliferation of effector T cells. Thus, the low levels of TGF-β could 
mean that there is decreased immunosuppression. However, additional experiments that involve 
co-culturing MDSCs and T cells with the agonists, would provide information on the overall 
immunosuppressive activity.  
Moreover, it is interesting that only R848 treated splenocytes released detectable levels of IL-12 
and IFN-γ in the whole splenocyte culture. However, the lower than detectable amounts of these 
cytokines could be due to the excessive levels of MDSCs in culture that is minimizing the 
number of antigen presenting cells, the source of these cytokines. By repeating the experiment 
using splenocytes isolated from a smaller tumor bearing mice, we could obtain conclusive 
evidence.  
E. Conclusion  
Despite growing research on the effect of TLR agonists on the immunosuppressive activity of 
MDSCs, literature lacks a direct comparison between the different agonists. Additionally, the 
effect of these agonists is usually tested only on isolated MDSCs, which fail to mimic the actual 
immune response in-vivo. By directly comparing the effect of different TLR agonists on MDSCs 
in splenocyte culture, we established the immunological differences between them. Though 
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further T cell activation and in-vivo studies are required to come to conclusions, we found that 
focus needs to be on Pam, LPS, FSL-1 and R848, which had direct impact on MDSC maturation. 
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F. Tables and figures 
Table 1. List of TLR agonists and their concentrations that were tested. The low 
concentration for each agonist used in this study, is the standard concentration at which it is used 
in literature for in-vitro studies. On the other hand, the higher concentrations were selected such 
that they were ten times that of the standard.   
 
TLR  
TLR 
agonist 
Concentration  
Reference Low High 
TLR1/2 Pam 20ng/ml 200ng/ml (18) 
TLR3 Poly IC 20ug/ml 200ug/ml (17) 
TLR4 LPS 0.1ug/ml 1ug/ml (20) 
TLR5 FLA-ST 10ng/ml 100ng/ml (21) 
TLR2/6 FSL-1 10ng/ml 100ng/ml (22) 
TLR7/8 R848 10ng/ml 100ng/ml (18, 23) 
 
 
 
Figure 1. Expression of TLRs 1-8 by MDSCs. Balb/cByJ mouse was subcutaneously injected 
with 1x106 4T1 cells. When the tumor volume reached about 500-700mm3, mice were sacrificed 
and splenocytes were isolated. Single cell suspensions of splenocytes were first incubated with 
purified rat anti-mouse CD16/CD32 for 10 minutes, to block non-specific Fc receptor mediated 
antibody binding. Further, the cells were stained with fluorochrome conjugated anti-CD11b, anti-
Ly6G and Ly6C and all anti-TLRs from 1-8. Cells stained with fluorochrome-conjugated mouse 
IgG1 kappa antibodies served as isotype control. The samples were acquired using FACScantoII 
and the expression of TLRs 1-8 by MDSCs were determined using FlowJo software. 
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Figure 2. Expression of MDSC maturation markers upon treatment with TLR agonists. 
Balb/cByJ mice were subcutaneously injected with 1x106 4T1 cells and spleens were isolated 
when the tumor volumes reached about 500-700 mm3. Splenocytes were isolated via mechanical 
dissociation and single cell suspensions obtained. Cells were then maintained in media 
containing 20ng/ml or 200ng/ml Pam; 20ug/ml or 200ug/ml Poly IC; 0.1ug/ml or 1ug/ml LPS; 
and 10ng/ml or 100ng/ml FLA-ST, FSL-1 or R848 for 3 days. 24 and 72 hours after treatment, 
cells were stained for MDSCs (anti-CD11b and anti-Ly6G and Ly6C) and maturation markers 
CD80, CD86, MHCII and F4/80. Cells treated with GM-CSF alone served as control. The 
samples were acquired using FACScantoII. The levels of expression of maturation markers 
CD80 (a), CD86 (b), MHCII (c) and F4/80 by MDSCs treated with each TLR agonist (low and 
high concentration) was determined using FlowJo software. The experiment was repeated thrice 
and a representative for each treatment is shown.  
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Figure 3. Gating strategy for MDSCs and CD11c positive cells. Balb/cByJ mice were 
subcutaneously injected with 1x106 4T1 cells and the spleen was isolated when the tumor 
volume reached about 500-700 mm3. Splenocytes were isolated via mechanical dissociation and 
single cell suspensions obtained. The cells were stained with fixable viability stain 660 and 
fluorochrome-conjugated mAb against CD11b, CD11c and Ly6G and Ly6C. Using 
FACScantoII, the samples were acquired, followed by analysis using FlowJo software to gate for 
live MDSCs (CD11b+ and Ly6G and Ly6C+) and CD11c+ cells.  
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Figure 4. Gating strategy for B cells, T cells and Tregs. Balb/cByJ mice were subcutaneously 
injected with 1x106 4T1 cells and spleens were isolated when tumor volumes reached about 500-
700 mm3. Splenocytes were isolated via mechanical dissociation and single cell suspensions 
obtained. The cells were stained with fixable viability stain 660 and fluorochrome-conjugated 
anti-CD3, anti-CD4, anti-CD25 and anti-FoxP3.  Using FACScantoII, the samples were acquired 
and the positive gates for live B cells (CD19+), T cells (CD3+) and Tregs (CD3+, CD4+, CD25+ 
and FoxP3+) were determined using FlowJo software.  
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Figure 5. Effect of lower dose of TLR agonists on immune cell subsets Balb/cByJ mice were 
subcutaneously injected with 1x106 4T1 cells and spleens were isolated when tumor volumes 
reached about 500-700 mm3. Splenocytes were isolated via mechanical dissociation and single 
cell suspensions obtained. Cells were then maintained in media containing 20ng/ml Pam, 
20ug/ml Poly IC, 0.1ug/ml LPS and 10ng/ml FLA-ST, FSL-1 or R848 for 3 days. 24 and 72 
hours after treatment, cells were stained for MDSCs (CD11b+ and Ly6G and Ly6C+), B cells 
(CD19+), CD11c+ cells and T cells (CD3+) and acquired using FACScantoII. Cells treated with 
10ng/ml GM-CSF alone for 24 and 72 hours served as control. Absolute numbers of B cells (a), 
T cells (b), MDSCs (c) and CD11c+ cells (d) were determined upon analysis of the flow 
cytometric data using FlowJo software. The experiment was repeated thrice and the results are 
represented as mean ± standard error (*p<0.05, **p<0.01).  
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Figure 6. Effect of higher dose of TLR agonists on immune cell subsets. Balb/cByJ mice 
were subcutaneously injected with 1x106 4T1 cells and spleens were isolated when the tumor 
volumes reached about 500-700 mm3. Splenocytes were isolated via mechanical dissociation and 
single cell suspensions obtained. Cells were then maintained in media containing 200ng/ml Pam, 
200ug/ml Poly IC, 1ug/ml LPS and 100ng/ml FLA-ST, FSL-1 or R848 for 3 days. 24 and 72 
hours after treatment, cells were stained for MDSCs (CD11b+ and Ly6G and Ly6C+), B cells 
(CD19+), CD11c+ cells and T cells (CD3+) and acquired using FACScantoII. Cells treated with 
10ng/ml GM-CSF alone for 24 and 72 hours served as control. Absolute numbers of B cells (a), 
T cells (b), MDSCs (c) and CD11c+ cells (d) were determined upon analysis of the flow 
cytometric data using FlowJo software. The experiment was repeated thrice and the results are 
represented as mean ± standard error (*p<0.05, **p<0.01).  
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Figure 7. Cytokine release at lower dose of TLR agonists. Balb/cByJ mice were 
subcutaneously injected with 1x106 4T1 cells and the spleen was isolated when tumor volumes 
reached about 500-700 mm3. Splenocytes were isolated via mechanical dissociation and single 
cell suspensions obtained. Cells were then maintained in media containing media containing 
20ng/ml Pam, 20ug/ml Poly IC, 0.1ug/ml LPS and 10ng/ml FLA-ST, FSL-1 or R848 for 3 days. 
24 and 72 hours after treatment, cell culture media was collected and centrifuged to remove any 
non-adherent cells. The cell culture supernatant was then tested for IL-6, IL-10 and TNF using 
CBA, whereas TGF-β and IL-12 were detected via cytokine specific ELISA. The experiment 
was repeated thrice and the concentration of IL-6 (a), IL-10 (b), TNF (c), TGF-β (d) and IL-12 
(d) released per 106 splenocytes were represented as mean ± standard error (*p<0.05, **p<0.01). 
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Figure 8. Cytokine release at higher dose of TLR agonists. Balb/cByJ mice were 
subcutaneously injected with 1x106 4T1 cells and spleens were isolated when tumor volumes 
reached about 500-700 mm3. Splenocytes were isolated via mechanical dissociation and single 
cell suspensions obtained. Cells were then maintained in media containing media containing 
200ng/ml Pam, 200ug/ml Poly IC, 1ug/ml LPS and 100ng/ml FLA-ST, FSL-1 or R848 for 3 
days. 24 and 72 hours after treatment, cell culture media was collected and centrifuged to remove 
any non-adherent cells. The cell culture supernatant was then tested for IL-6, IL-10 and TNF 
using CBA, whereas TGF-β, IL-12 and IFN-γ were detected via cytokine specific ELISA. The 
experiment was repeated thrice and the concentration of IL-6 (a), IL-10 (b), TNF (c), TGF-β (d), 
IL-12 (d) and IFN-γ (e) released per 106 splenocytes were represented as mean ± standard error 
(*p<0.05, **p<0.01). 
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V. CONCLUSION 
Autologous tumor cell vaccines generated using inactivated tumor cells from self, is a promising 
strategy to treat highly heterogeneous cancers such as breast carcinoma. ATCVs contain all 
tumor associated antigens both known and unknown, thereby increasing the likelihood of a 
polyclonal immune response. Additionally, ATCVs also minimize the possibility of tumor 
escape through downregulation of tumor antigens, which is a common drawback of the other 
immunotherapies such as monoclonal antibody based therapy.  
However, a major hindrance in the clinical translation of ATCVs is their poor immunogenicity. 
When tumor flourishes in the body, it develops a variety of mechanisms that help it from being 
recognized by the immune system. For instance, it downregulates the expression of major 
histocompatibility complexes (MHC I/II) and other costimulatory molecules that are required to 
generate a robust anti-tumor immune response. Since ATCVs are generated using these cancer 
cells, despite the potential to induce a polyclonal immune response, they greatly fail. Though 
several investigators have proposed the use of adjuvants such as GM-CSF to aid in enhancing the 
immune response, there has been no success so far in extremely heterogeneous and inherently 
aggressive cancers such as breast carcinoma.  
Thus, in this research, we set out to determine the underlying reasons for the poor 
immunogenicity of ATCVs against highly aggressive breast cancers. To do this, we used two 
murine breast cancer cell lines, 4T1 and EMT6, that are on the opposite sides of the spectrum of 
metastatic capability. 4T1 is a highly metastatic and aggressive murine breast cancer cell line 
known to imitate human stage IV breast cancer. On the other hand, EMT6 is a non-metastatic 
murine breast cancer cell line. ATCVs against each cell line was generated upon irradiation at 
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100Gy using a cesium irradiator. When mice are vaccinated with the irradiated 4T1 or EMT6 
cells and challenged with respective 4T1 or EMT6 live cells, we found that the vaccine efficacy 
of the two ATCVs greatly varied. With the 4T1 vaccine group, none of the mice developed any 
anti-tumor immunity to live 4T1 challenge. Whereas, 70% of the mice in the EMT6 vaccinated 
group, rejected a live EMT6 challenge. Thus, we set out to use these two murine breast cancer 
cells of varying levels of immunogenicity, to determine the underlying reasons for the poor 
immunogenicity of breast cancer ATCVs.  
First to understand why 4T1 ATCV did not develop protective immunity, we determined the 
levels of expression of surface molecules MHC I, MHC II, B7-1, B7-2, ICAM-1 and Fas 
receptor expressed by both 4T1 and EMT6 cells. Since these surface molecules are essential for a 
robust immune response, differences in their levels of expression could result in the differences 
in their ATCV immunogenicity. We found that irradiated EMT6 cells express high levels of B7-
1 and Fas receptor when compared to irradiated 4T1 cells. We initially suspected, upregulation 
of these molecules to be responsible for the improved protective immunity against EMT6 cells.  
However, in addition to the above-mentioned surface molecules, an effective immune response 
would also depend on cytokines produced by tumor cells in the ATCV. If high levels of 
cytokines that promote cancer cell proliferation and increased immunosuppression are generated 
by an ATCV, it could greatly inhibit an effective anti-tumor immune response. Thus, in addition 
to the surface molecules, we also looked for differences in some of the cancer promoting or 
immunosuppressive cytokines produced by the irradiated cells. We found that 4T1 cells produce 
exceptionally high levels of immunosuppressive cytokines G-CSF and GM-CSF and 
significantly high levels of IL-6 and MCP-1.  
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Thus, based on the excessive levels of some of these cytokines, especially G-CSF by 4T1 cells, 
we suspected the differences in immunogenicity to be likely due to immunosuppression 
associated generated by these cytokines. We explored this possibility by generating ipsilateral 
and contralateral hybrid vaccines that included irradiated 4T1 cells along with EMT6 vaccine, on 
the same and opposite sides respectively and challenged with live EMT6 cells. Thus, a drop in 
the overall survival in any of the two groups when compared to EMT6 vaccine group, would 
imply the possibility of 4T1 based immunosuppression to affect the vaccine efficacy.  
We found that in both the hybrid vaccine groups, the overall survival drastically dropped upon 
inclusion of irradiated 4T1 cells. Only 40% and 25% of mice in the ipsilateral and contralateral 
vaccine groups developed protective immunity to EMT6 challenge, respectively. Since, the 
contralateral hybrid vaccine also affected the immune response, it implied that the 4T1 based 
immunosuppression is systemic, rather than local. Thus, we suspected that the 
immunosuppressive cytokines and not the surface molecules, expressed by the irradiated 4T1 
cells is affecting the overall vaccine efficacy. Here, of the different immunosuppressive 
cytokines, G-CSF was produced at exceptionally high levels (20 times more) by 4T1 cells. Thus, 
we hypothesized that it plays a key role in determining the overall efficacy of the vaccine.  
To test this hypothesis, we used the loss of function approach, where we eliminated G-CSF in 
4T1 by knocking out the gene via CRISPR/Cas9 technology (4T1.G-CSF KO). Successful knock 
out was first verified in-vitro by measuring the levels of G-CSF in cell free culture media 
collected from these cells. It was further verified in-vivo, by analyzing the concentration of 
serum G-CSF isolated from mice bearing 4T1.G-CSF KO cells. The serum G-CSF levels were 
significantly less in 4T1.G-CSF KO mice when compared to serum collected from mice with 
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comparable 4T1 tumor volumes (500-700mm3). Thus, in this study, the 4T1 and 4T1.G-CSF KO 
cells were used as a model to test for the effect of G-CSF in ATCV efficacy.  
By implanting 4T1 and 4T1.G-CSF KO cells in mice, we found that tumor derived G-CSF 
causes immunosuppression via the accumulation of immunosuppressive myeloid cells known as 
MDSCs, in spleen and DLN of tumor bearing mice. Further, a significant difference in the levels 
of T cells, B cells and Tregs were also found in the spleen of 4T1.G-CSF KO bearing mice, 
when compared to mice with 4T1 tumors. Though there was decrease in the levels of these 
immune cells in the DLN too, the difference was significant only for the T cells.  
However, colony stimulating factors such as G-CSF are often associated with resulting in the 
excessive expansion of MDSCs in tumor microenvironment. Thus, to determine a correlation 
between G-CSF and MDSC levels, we used four other breast cancer cell lines, namely 4T07, 
67NR, 168FARN and 66Cl4 that naturally released varying levels of G-CSF. We found that the 
levels of serum G-CSF in mice bearing these tumors, closely correlated with the frequency of 
splenic MDSCs. Hence, we further established the effect of G-CSF on MDSC expansion in 
breast cancers.   
Therefore, we then set out to determine if the tumor derived G-CSF was also responsible for 
affecting the vaccine efficacy of these cells in an ATCV setting. To do this, we included 
irradiated 4T1.G-CSF KO cells in the contralateral vaccine instead of 4T1 cells and challenged 
the mice with live EMT6 cells. We found that the inclusion of 4T1.G-CSF KO cells instead of 
4T1 cells, greatly improved the vaccine efficacy as only 30% of the mice developed tumors. 
Additionally, when we vaccinated and challenged mice with 4T1.G-CSF KO cells, none of the 
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mice developed tumors. Thus, for the first time, the findings from this study established a causal 
link between tumor derived G-CSF and poor anti-tumor immune response to ATCV.  
Further, in this research, we wanted to address this MDSC based immunosuppression in breast 
cancers, by determining strategies to induce maturation of immature myeloid cells into mature 
monocytes and dendritic cells. As a step in this direction, we compared the effect of different 
TLR agonists namely, Pam, Poly IC, LPS, FLA-ST, FSL-1 and R848 on MDSC maturation in-
vitro. However, unlike previous studies where the MDSCs were isolated to study their 
maturation, we treated whole splenocyte cultures with the TLR agonists and studied their effect 
on MDSC maturation. We believe that this would closely mimic in-vivo events where MDSCs 
would receive signals and cytokines from other immune cells that would play an important role 
in deciding the fate of these cells.   
Our studies showed that not all TLRs have similar effect on MDSC maturation. Pam, which is a 
TLR1/2 agonist, was found to be the most effective of all the TLRs tested, since it upregulated 
the expression of all four markers of maturation on the MDSCs. Other agonists, namely FSL-1 
and LPS, only upregulated CD80 and F4/80 expression, whereas R848 upregulated MHCII and 
F4/80. On the other hand, agonists Poly IC and FLA-ST did not have any effect on MDSC 
maturation. Additionally, we also found that there was significant decrease in the number of 
MDSCs only in cultures treated with Pam, LPS and FSL-1.   
Further, to get more information on the effect of the agonists on immune response, we also 
determined the number of other immune cells, namely T cells, B cells, Tregs and CD11c+ cells 
in the splenocyte cultures treated with the agonist. Though we found LPS to decrease number of 
T cells; Poly IC to decrease the number of CD11c+ cells and all agonists to decrease the number 
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of B cells at either the low or high concentration, we couldn’t make any conclusive comments on 
their overall effect on the immune response.  
Additionally, when we looked at the levels of different cytokines in the cultures treated with the 
agonists, we found that only the agonists that had any effect on MDSC maturation markers (Pam, 
LPS, FSL-1 and R848), had significantly high levels of IL-6, IL-10, TNF and low levels of TGF-
β. Since all these cytokines have both pro-tumor and anti-tumor response, further studies are 
required to determine their overall effect on the immune response.   
Thus, to summarize, the findings of this study have established the significant role played by 
tumor derived G-CSF in abrogating the anti-tumor immune response to ATCVs in breast cancer. 
Since this was found to be largely due to immunosuppression via MDSC accumulation, agonists 
such as Pam and FSL-1 were identified to potentially eliminate the immunosuppression via 
initiating the maturation of these cells into monocytes and macrophages.  
Considering some of the future directions that this research could take, involves exploring the 
likelihood of using serum G-CSF as an indicator of tumor burden or clinical cancer stage in 
breast cancer patients. Additionally, in this study, we also noticed a close correlation between 
tumor derived G-CSF levels and the metastatic ability of the cancer cells. Thus, we believe that 
there is a possibility for the existence of a causal link between tumor derived G-CSF and 
metastasis in breast cancer. Further, since MDSCs also affect the expansion of Tregs, previous 
studies that have determined a correlation between tumor burden and levels of Tregs could be 
due to high G-CSF secretion.   
Additionally, the scope of this study was limited, as only in-vitro studies were performed with 
the TLR agonists. Studies that compare the effects of these agonists in-vivo would help us pick 
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out an agonist that would have the highest potential to eliminate the MDSC associated 
immunosuppression in breast cancer. Further, treatment strategies involving the agonist in an 
adjuvant setting, could improve the overall survival of breast cancer patients.  
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VI. APPENDIX 
A. Materials 
Reagents 
Mouse recombinant IL-12 (rIL-12) and 2-mercaptoethanol used in maintaining 2D6 culture was 
obtained from Sigma Aldrich (St. Louis, MO) and University of Arkansas Biologics center 
(Fayetteville, AR), respectively. Recombinant mouse granulocyte-monocyte colony stimulating 
factor (rGM-CSF) used in maintaining the viability of MDSCs in culture, were purchased from 
Sigma-Aldrich (St. Louis, MO).  All fluorochrome conjugated monoclonal antibodies (mAb) 
used in the detection of different immune cell subsets were purchased from BD Biosciences (San 
Jose, CA).  
Cell culture media components including Dulbecco’s modified eagle medium (DMEM), Roswell 
Park Memorial Institute-1640 (RPMI-1640) medium, fetal bovine serum (FBS) and 
penicillin/streptomycin were purchased from Hyclone laboratories (Marlborough, MA). 
Ammonium-chloride-potassium (ACK) buffer used in the lysis of red blood cells while isolating 
splenocytes, was purchased from Lonza (Allendale, NJ).      
Cell culture 
4T1 (murine breast cancer cell line) was purchased from American Type Culture Collection 
(ATCC) (Manassas, VA, USA) and maintained in DMEM supplemented with 10% FBS and 1% 
penicillin/streptomycin. 2D6 cells were a generous gift from Dr. David Klinke, West Virginia 
University and maintained in RPMI 1640 supplemented with 10% FBS, 1% 
penicillin/streptomycin and 2µM of 2-mercaptoethanol. Splenocytes from tumor bearing mice 
were isolated following the procedure described below. Isolated splenocytes were treated with 
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10ng/ml rGM-CSF and with/without IL-12 (20ng/ml or 200ng/ml) in RPMI-1640 medium 
supplemented with 10% FBS and 1% penicillin/streptomycin. All cell cultures were maintained 
in a humidified CO2 incubator with 5% CO2 at 37˚C.  
Mice 
Female Balb/cByJ mice were purchased from The Jackson Laboratory (Bar Harbor, ME, USA) 
and were housed in microisolator cages. All experimental procedures were approved by the 
Institutional Animal Care and Use Committee at University of Arkansas. Mice were utilized for 
experiments at 8-12 weeks of age and animal care followed ‘The Guide for Care and Use of 
Laboratory Animals’ (National Research Council). 
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B. Figures 
           
Figure 1. IL-12 receptor expression by granulocytic and monocytic MDSCs. Balb/cByJ 
mouse was subcutaneously injected with 1x106 4T1 cells. When the tumor volume reached about 
500-700 mm3, mice were sacrificed and splenocytes were isolated. Granulocytic (Gr1high Ly6G+) 
and monocytic (Gr1dim and Ly6G-) MDSCs were isolated using the myeloid derived suppressor 
kit from Miltenyi Biotech. The sorted cells were incubated with fluorochrome-conjugated anti-
IL-12 receptor β1 (IL-12Rβ1) and a combination of anti-IL-12 receptor β2 antibody (IL-12Rβ2) 
and fluorochrome-conjugated secondary antibody. Cells were blocked with 1% BSA. 2D6 cells 
cultured in media containing 250pg/ml recombinant IL-12, were washed and incubated with 
fluorochrome-conjugated anti-IL-12 receptor β1and a combination of anti-IL-12 receptor β2 
antibody and fluorochrome-conjugated secondary antibody. These cells served as positive 
control. Unstained sorted granulocytic and monocytic MDSCs served as negative control. The 
samples were acquired using FACScantoII and the expression of IL-12Rβ1 and IL-12Rβ2 by 
granulocytic MDSCs (a) and monocytic MDSCs (b) were analyzed using FlowJo software.      
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Figure 2. Levels of expression of maturation markers on MDSCs. Balb/cByJ mice were 
subcutaneously injected with 1x106 4T1 cells and spleens were isolated when tumor volumes 
reached about 500-700 mm3. Splenocytes were isolated via mechanical dissociation and single 
cell suspensions obtained. Cells were then maintained in media containing 20ng/ml (low conc.) 
and 200ng/ml (high conc.) IL-12 for 3 days. 24 and 72 hours after treatment, cells were stained 
for MDSCs (anti-CD11b and anti-Ly6G and Ly6C) and maturation markers CD80, CD86, 
MHCII and F4/80. Cells treated with GM-CSF alone served as control. The samples were 
acquired using FACScantoII and the levels of expression of the maturation markers by MDSCs 
were analyzed using FlowJo software.   
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Figure 3. Number of B cells, T cells, MDSCs and CD11c+ cells in splenocytes treated with 
IL-12 in-vitro. Balb/cByJ mice were subcutaneously injected with 1x106 4T1 cells and the 
spleen was isolated when the tumor volume reached about 500-700 mm3. Splenocytes were 
isolated via mechanical dissociation and single cell suspensions obtained. Cells were then 
maintained in media containing 20ng/ml and 200ng/ml IL-12 for 3 days. 24 and 72 hours after 
treatment, cells were stained for B cells (CD19+), MDSCs (CD11b+ and Ly6G and Ly6C+), T 
cells (CD3+) and CD11c+ cells. The samples were acquired via FACScantoII and analyzed 
using FlowJo software. Number of B cells, T cells, MDSCs and CD11c+ cells with 24-hour (a) 
and 72-hour (b) treatment with IL-12 were determined. The experiment was repeated thrice and 
the results represent mean ± standard error. 
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Figure 4. Cytokines IL-6, TNF and TGF-β released upon treatment with IL-12 for 24 and 
72 hours. Balb/cByJ mice were subcutaneously injected with 1x106 4T1 cells and the spleen was 
isolated when the tumor volume reached about 500-700 mm3. Splenocytes were isolated via 
mechanical dissociation and single cell suspensions obtained. Cells were then maintained in 
media containing 20ng/ml and 200ng/ml of IL-12 for 3 days. 24 and 72 hours after treatment, 
cell culture media was collected and centrifuged to remove any non-adherent cells. The cell 
culture supernatant was then tested for IL-6 and TNF using CBA, whereas TGF-β was detected 
via TGF-β specific ELISA. The experiment was repeated thrice and the 24-hour (a) and 72-hour 
(b) cytokine release were represented as mean ± standard error.  
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